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T celler i bronkialskyllevæske ved sarkoidose og andre interstitielle 
lungesykdommer 
Vi fant økt forekomst av T celler med naturlig drepecelle-markører (NKT celler) hos 
pasienter med hypersensitivitets pneumonitt sammenlignet med sarkoidose, og 
uttrykket av aktiveringsmarkøren HLA-DR på cytolytiske T celler var betydelig 
høyere ved hypersensitivitets pneumonitt. Tilsammen ser det ut til at disse to 
lymfocyttfenotypene kan gi en god diskriminering mellom pasienter med sarkoidose 
og hypersensitivitets pneumonitt. Videre undersøkte vi diagnostisk nøyaktighet av en 
test basert på immunceller i bronkoalveolær skyllevæske ved diagnostikk av 
sarkoidose. NKT celler og aktiveringsgrad på cytolytiske T celler ga en signifikant 
økning av testens diagnostiske nøyaktighet.  
I den siste artikkelen viser vi at både fraksjoner av regulatoriske T celler og Th17 
celler i bronkoalveolær skyllevæske var lavere hos pasienter med sarkoidose enn hos 
friske kontroller og fant at en stor andel av Th17 cellene hos pasienter med sarkoidose 
også produserte interferron-γ. Andelen interferron-γ+ Th17 celler var sterkt korrelert 
med andel Th1 celler, men også med alvorlighetsgrad av sykdommen. Dette kan være 
en effekt av en Th17-Th1 drift som følge av en intens Th1-respons. 
Dette forskningsarbeidet viser at lymfocyttfenotyper kan øke diagnostisk nøyaktighet 
av immuncelleprofiler ved sarkoidose, og potensielt også ved hypersensitivitets 
pneumonitt. 
Slimhinnen i luftveiene og lungene er kontinuerlig eksponert for partikler, støv og en 
stor mengde mikrober fra omgivelsene. T hjelpeceller orkestrerer forskjellige typer 
spesifikke immunresponser, passende for den aktuelle trusselen. Th1 celler og Th17 
celler skiller ut de betennelsesfremmende signalstoffene interferron-γ og IL-17, mens 
regulatoriske T har en regulatorisk og dempende effekt på immunresponsen. 
Immunceller fra lungene kan framskaffes ved fiberoptisk bronkoskopi med 
bronkoalveolar lavage, og undersøkes nærmere med flow cytometri.  
Målet med dette forskningsprosjektet var å lete etter immuncelleprofiler og 
lymfocyttfenotyper som kan brukes i diagnostikk av sarkoidose eller 
hypersensitivitets pneumonitt, samt å undersøke balansen mellom de forskjellige 
undergruppene av T hjelperceller ved sarkoidose og friske kontroller. 
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NORSK SAMMENDRAG 
 
Slimhinnen i luftveiene og lungene er kontinuerlig eksponert for partikler, støv og en stor 
mengde mikrober fra omgivelsene. Ufarlige mikrober og partikler fjernes med minst mulig 
betennelsesreaksjon i vevet, slik at lungenes gassutveksling kan opprettholdes. I 
normalsituasjonen sørger alveolære makrofager for dette, mens de skiller ut immundempende 
signalstoffer. Lymfocyttene i lungene er hovedsakelig T celler. T hjelpeceller utrykker co-
reseptoren CD4 på celleoverflaten, og orkestrere forskjellige typer spesifikke 
immunresponser, passende for den aktuelle trusselen, og deles inn etter hvilke signalstoffer de 
produserer og skiller ut. Th1 celler skiller ut det betennelsesfremmende signalstoffet 
interferron-γ, Th2 celler skiller ut IL-4 og Th17 celler skiller ut IL-17. Regulatoriske T celler 
er en populasjon med CD4+ T celler som uttrykker transkripsjonsfaktoren FoxP3, og har en 
regulatorisk og dempende effekt på immunresponsen.  
Immunceller fra lungene kan framskaffes ved fiberoptisk bronkoskopi med bronkoalveolar 
lavage, der man skyller et lungesegment med saltvann eller buffer via arbeidskanalen i 
bronkoskopet. Cellene i skyllevannsprøven kan undersøkes nærmere med flow cytometri, som 
muligjør analyser av blant annet uttrykk av antigener på celleoverflaten, produksjon av 
signalstoffer, funksjonell status og aktiveringsgrad på hver enkelt celle. Samtidig kan man 
måle relativ forekomst av de forskjellige immuncelletypene. Enkelte inflammatoriske 
sykdommer kan ha et mer eller mindre spesifikt mønster av immunceller, og kunnskap om 
dette kan i noen sammenhenger brukes til å sannsynliggjøre hvilken sykdom en pasient lider 
av. Dessuten kan man øke kunnskapen om de forskjellige sykdommene ved å studere mønstre 
i immunresponsen. Forholdet mellom forekomst av forskjellige undergrupper av T celler har 
blitt knyttet til enkelte autoimmune sykdommer.  
Sarkoidose er en inflammatorisk sykdom som kan ramme nærmest alle vev i kroppen, og 
kjennetegnes av akkumulering av Th1 celler og betennelsesknuter kalt granulomer i lunger og 
lymfevev. En lignende granulomatøs lungesykdom med uttalt Th1 respons er 
hypersensitivitets pneumonitt, som kan oppstå ved eksponering for en rekke forskjellige 
stoffer, hovedsakelig antigener fra inhalert organisk støv, som sopp, bakterier eller proteiner 
fra fugler. Årsaken til sarkoidose er ennå ukjent, men man mistenker at inhalasjon av et eller 
flere ukjente antigen utløser sykdommen.. 
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Målet med dette forskningsprosjektet var å lete etter immuncelleprofiler og 
lymfocyttfenotyper som kan brukes i diagnostikk av sarkoidose eller hypersensitivitets 
pneumonitt, samt å undersøke forekomsten av og balansen mellom de forskjellige 
undergruppene av CD4+ T celler ved sarkoidose og friske kontroller. 
Vi fant økt forekomst av T celler med naturlig drepecelle-markører (NKT celler) hos pasienter 
med hypersensitivitets pneumonitt sammenlignet med sarkoidose (median 5.5% versus 0.7% 
av leukocyttene, p<0.0001). Videre var uttrykket av aktiveringsmarkøren HLA-DR på 
cytolytiske T celler (CD8+) betydelig høyere hos pasienter med hypersensitivitets pneumonitt 
sammenlignet med sarkoidose. (median 79% versus 43%, p<0.0001). Tilsammen ser det ut til 
at de to lymfocyttfenotypene NKT celler og HLA-DR+ CD8+ T celler kan gi en god 
diskriminering mellom pasienter med sarkoidose og hypersensitivitets pneumonitt. Videre 
undersøkte vi diagnostisk nøyaktighet av en test basert på data fra bronkoalveolær 
skyllevæske hos pasienter som ble utredet med mistanke om sarkoidose eller andre lignende 
lungesykdommer. Ved hjelp av ROC (receiver operating characteristic)-kurve analyser kunne 
vi anslå testens diagnostiske nøyaktighet med eller uten tillegg av NKT cellefraksjon og 
HLA-DR+ CD8+ T celler. Arealet under ROC kurven var henholdsvis 0.937 og 0.898 
(p=0.008). Tillegg av disse to lymfocyttfenotypene i vår prediksjonsmodell ga en signifikant 
økning av testens diagnostiske nøyaktighet.  
I den siste artikkelen viser vi at både fraksjoner av regulatoriske T celler og Th17 celler i 
bronkoalveolær skyllevæske var lavere hos pasienter med sarkoidose enn hos friske kontroller 
(median: 3.4% versus 5.3%, p=0.017 og 2.5% versus 4.5%, p=0.01). Videre fant vi at en stor 
andel av Th17 cellene hos pasienter med sarkoidose også produserte interferron-γ (median: 
72.4% versus 31% hos friske kontroller, p=0.0005). Andelen interferron-γ+ Th17 celler var 
sterkt korrelert med andel Th1 celler, men også med alvorlighetsgrad av sykdommen uttrykt 
ved radiologisk stadium (n=23, rho=0.45, p=0.03). 
Dette forskningsarbeidet viser at lymfocyttfenotyper kan øke diagnostisk nøyaktighet av 
immuncelleprofiler fra bronkoalveolær skyllevæske ved sarkoidose, og potensielt også ved 
hypersensitivitets pneumonitt. Videre fant vi at hovedparten av Th17 celler i bronkoalveolær 
skyllevæske hos pasienter med sarkoidose produserte interferron-γ. Dette kan være en effekt 
av en Th17-Th1 drift som følge av en intens Th1-respons. 
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SUMMARY IN ENGLISH 
 
The lungs and airways are constantly exposed to inhaled particles and microbes from the 
environment. To maintain the integrity of the lung epithelial surfaces, non-virulent microbes 
and particulate matter must be removed without unnecessary inflammation, whereas an 
effective immune response must be mounted towards potentially harmful pathogens. In 
health, this multifaceted task is handled by lung epithelial cells and the dominating population 
of scavenger cells, alveolar macrophages, which exert an array of immunosuppressive signals. 
The mucosal immune cells also include a population of lung homing lymphocytes of the 
memory phenotype, mostly T cells, capable of mounting a specific immune response towards 
formerly encountered pathogens or virus infected cells. T helper cells express CD4, and can 
release proinflammatory cytokines when activated via the T cell receptor, orchestrating an 
appropriate response to the offending threat. CD4+ T cells are principally subdivided into 
subsets by their cytokine profile, including IFN-γ (Th1), IL-4 (Th2) and IL-17 (Th17). 
Another subset of CD4+ T cells expresses the transcription factor FoxP3 (regulatory T cells), 
and exerts regulatory effects on the immune response.  
During bronchoscopy, immune cells from the mucosa of the lungs and airways can be 
obtained by bronchoalveolar lavage, in which fluid is instilled and retrieved from a segmental 
bronchus. Flow cytometry is an essential tool in immunology, and enables us to characterize 
the phenotype, cytokine profile and quantify the frequencies of T cell subsets in 
bronchoalveolar lavage fluid. The immune cell profile in affected tissues of an inflammatory 
disorder may in some settings be of diagnostic value, as different disorders tend to have 
particular patterns of immune cell phenotypes or activation states. Additionally, altered 
balance of T helper cell subsets may be harmful to the patient. As an example, the failure to 
produce functional regulatory T cells causes devastating autoimmunity.   
Sarcoidosis is a multisystem inflammatory disorder characterized by an accumulation of Th1 
cells in the lungs and lymphatics. Granulomas, nodular collections of giant cells, epithelioid 
histiocytes, and chronic inflammatory cells, are frequently seen. Another granulomatous lung 
disease with accumulation of Th1 cells in the lungs and alveoli is hypersensitivity 
pneumonitis. The granulomatous reaction in hypersensitivity pneumonitis can be caused by a 
vast number of antigens, mostly proteins from inhaled organic dusts, whereas the offending 
agent in sarcoidosis is unknown.  
18 
The aim of the present studies was to identify bronchoalveolar lavage fluid profiles and 
lymphocyte phenotypes that can be used in the diagnosis of sarcoidosis and hypersensitivity 
pneumonitis, and to explore the frequency and balance of regulatory T cells and Th17 cells in 
the Th1-polarized disorder sarcoidosis and in healthy control subjects. 
In patients with hypersensitivity pneumonitis, the frequency of T cells expressing the natural 
killer cell markers  (NKT cells) was prominently increased compared to sarcoidosis (median 
5.5% versus 0.7% of leucocytes, p<0.0001).  The fraction of cytolytic (CD8+) T cells 
expressing the activation marker HLA-DR was also considerably higher in hypersensitivity 
pneumonitis (median 79% versus 43%, p<0.0001). The expression of HLA-DR in CD4+ T 
cells was higher in hypersensitivity pneumonitis, although not as markedly (89% versus 69%, 
p=0.0002). When viewed together, fraction of NKT cells and HLA-DR+ CD8+ T cells seem to 
discriminate patients with hypersensitivity pneumonitis from sarcoidosis. These two markers 
were tested in a retrospective study on the diagnostic accuracy of bronchoalveolar lavage fluid 
data in discriminating sarcoidosis from a diverse population of patients investigated for 
possible diffuse parenchymal lung disease. We measured diagnostic accuracy as the area 
under the receiver operating characteristic curve (ROC curve). The area under the ROC curve 
for the prediction model with and without fractions of NKT cells and HLA-DR+ CD8+ T cells 
was 0.937 and 0.898, respectively (p=0.008). Thus, addition of these two markers increased 
the diagnostic accuracy of bronchoalveolar lavage fluid data in sarcoidosis.  
In the third paper we found that fractions of regulatory (FoxP3+ CD4+) T cells and Th17 cells 
were lower in sarcoidosis compared to healthy controls (median: 3.4% versus 5.3%, p=0.017 
and 2.5% versus 4.5%, p=0.01). Interestingly, the fraction of Th17 cells also producing the 
Th1 cytokine IFN-γ was more than two-fold greater in sarcoidosis (median: 72.4% versus 
31%, p=0.0005), and this fraction was highly correlated with fractions of Th1 cells. 
Moreover, the fraction of Th17 cells producing IFN-γ was positively correlated with severity 
of sarcoidosis, measured as radiologic stage (n=23, rho=0.45, p=0.03). 
In conclusion, these studies provide evidence that lymphocyte phenotypes can be used as 
diagnostic markers in sarcoidosis and possibly hypersensitivity pneumonitis. Furthermore, we 
found that the Th1 immune response in sarcoidosis is correlated with increased expression of 
IFN-γ in Th17 cells. This may be an indication of a Th17-Th1 drift in sarcoidosis, due to an 
intense Th1 response. 
Paper I
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1 INTRODUCTION 
1.1 GENERAL INTRODUCTION 
Since the 1970’s, studies on immune cells in bronchoalveolar lavage fluid (BALF) have had 
an immense effect on our understanding of the immune processes in normal and diseased 
lungs, and particularly so in sarcoidosis, an inflammatory granulomatous disease affecting the 
lungs. Research on sarcoidosis has a long tradition in Scandinavia since its initial description 
in 1899 [1].   
The airways and the lungs contain the greatest epithelial surface of the body, estimated to 
120m2 [2]. The scavenger cells of the lungs, the alveolar macrophages (AM) are specialized in 
removing foreign particles and microbes from the alveoli while suppressing unnecessary 
inflammation that may cause disruption of the respiratory membrane and compromise gas 
exchange[3]. Peptides from microbes are presented by dendritic cells (DC) or AM to cells of 
the adaptive immune system in pulmonary and mediastinal lymph nodes, and antigen-specific 
lymphocytes can be recruited to the lungs during an inflammatory response. 
The cellular profile and lymphocyte phenotypes in BALF may guide in the diagnosis of some 
diffuse parenchymal lung diseases (DPLD). However, the overlaps between various DPLD 
are considerable, and the debate on the usefulness of cellular investigations in BALF is still 
on going[4]. Modern flow cytometry enables increasingly complex profiling of the surface 
markers and intracellular protein expression in immune cells, providing a key tool in research 
on lung immunity both in health and disease.  
In the present project, we use flow cytometry to study BALF T cell phenotypes and cellular 
profiles both to explore the immune processes in inflammatory lung diseases and as 
diagnostic markers, focusing on sarcoidosis. 
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1.2 DIFFUSE PARENCHYMAL LUNG DISEASE 
 
DPLD [also called interstitial lung disease( ILD)] is a heterogeneous group of more than 150 
disease entities[5], characterized by acute or chronic bilateral parenchymal tissue 
inflammation or fibrosis, and without evidence of infection or neoplasia [6]. Throughout the 
last century, our understanding of the pathogenesis of DPLDs has increased rapidly, and a 
system of classification of these diseases has been made [7, 8]. The current classification of 
DPLD consists of disorders of known cause (including DPLD associated with drugs, radiation 
therapy or collagen vascular disease, hypersensitivity pneumonitis or pneumoconiosis) or 
unknown cause. DPLD of unknown cause is subdivided into the groups of idiopathic 
interstitial pneumonias, granulomatous DPLD (sarcoidosis) and a final group of other forms 
of DPLD (including eosinophilic pneumonia and pulmonary Langerhans’ cell 
histocytosis)[7]. Much attention has been paid to the idiopathic interstitial pneumonias, which 
are: idiopathic pulmonary fibrosis, idiopathic nonspecific interstitial pneumonia, respiratory 
bronchiolitis-interstitial lung disease, desquamative interstitial pneumonia, cryptogenic 
organizing pneumonia, acute interstitial pneumonia, idiopathic lymphoid interstitial 
pneumonia, idiopathic pleuroparenchymal fibroelastosis and unclassifiable idiopathic 
interstitial pneumonia[8]. 
Patients usually present with complaints of dyspnea on exertion or at rest. Cough is a common 
symptom as well. Symptoms and signs of extrapulmonary disease are important, as they may 
provide clues to an underlying disease, such as rheumatoid arthritis or inflammatory bowel 
disease. Thoracic imaging shows bilateral pulmonary infiltrates, and biopsy specimens show 
an accumulation of inflammatory immune cells, sometimes with abnormal extracellular 
matrix. BAL cellular analysis is a useful adjunct in patients with suspected DPLD. 
A multidisciplinary approach is recommended to obtain a diagnosis of the idiopathic 
interstitial pneumonias, as the patterns seen on high-resolution CT and lung biopsy specimens 
are overlapping between the different entities. Idiopathic interstitial pneumonias are 
frequently confused with hypersensitivity pneumonitis [8], and more specific diagnostic 
markers are sought after. 
In the following sections, we present a more detailed description of sarcoidosis and 
hypersensitivity pneumonitis.   
21 
1.3 SARCOIDOSIS 
Sarcoidosis is a multisystem inflammatory disorder of unknown etiology, affecting the lungs 
and intrathoracic lymph nodes in the majority of cases. The term ‘sarcoidosis’ is derived from 
a case report from 1899 by the Norwegian dermatologist Cæsar Boeck, who described the 
histologic appearance of a skin lesion with similarities to sarcoma, in an article titled 
"Multiple benign sarcoid of the skin" [1]. Patients often present in adulthood, with hilar 
lymphadenopathy and pulmonary infiltration, and sometimes eye and skin lesions[9], 
although almost any organ may be affected. The highest incidence of sarcoidosis is reported 
to be in northern European countries (5 to 40 cases per 100,000) [10] and amongst African 
Americans in United States (35.5 cases per 100,000) [9, 11], and the latter have more skin, 
liver and eye involvement, a more chronic course and worse prognosis[12].  
The most common symptom at presentation is persistent cough, and patients often have 
constitutional symptoms such as fatigue, low-grade fever or weight loss[13]. An incidental 
abnormal chest radiograph in an asymptomatic patient is also a frequent presentation[10]. 
Lung function test may show a volume restriction or an airflow limitation [13, 14]; the latter 
may indicate airway involvement [15, 16]. A reduced carbon monoxide diffusing capacity is a 
common finding. The typical high-resolution computed tomography (HRCT) features of 
sarcoidosis are bilateral hilar lymph node enlargement with a perilymphatic micronodular 
pattern and upper lobe predominance. It has been estimated that 95 % of patients with 
sarcoidosis have bilateral hilar lymph node enlargement [17]. Sarcoid granulomas are seen as 
micronodular lesions, and may coalesce over time, forming larger nodules[18].  
The granulomas of sarcoidosis are well-defined interstitial collections of giant cells, 
epithelioid histiocytes, and chronic inflammatory cells, with a lymphatic distribution 
(centrilobular in the bronchovascular bundle, interlobular septa and in the pleura). The 
granulomas are mostly non-necrotizing, and concentric hyaline fibrosis is often seen around 
the granulomas, while the interstitium, unlike in hypersensitivity pneumonitis (HP), does not 
show signs of inflammation apart from the granulomas[9]. Unfortunately, the granulomas in 
sarcoidosis do not have any unique histologic features that discriminate them from 
granulomas of other causes[10]. 
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Figure 1: Lung granulomas 
The large areas of consolidation represent confluent granulomas without significant fibrosis. Involved hilar 
lymph nodes are markedly enlarged (Yale Rosen, via Wikimedia Commons). 
Sarcoidosis is characterized by increased fraction and number of IFN-γ-producing T helper 
cells (Th1 cells) in inflamed tissue [19, 20], commonly the lungs and lymphatics. The inciting 
antigen in sarcoidosis remains unknown. According to a current hypothesis, a persistent and 
poorly degradable antigen provokes a Th1 type immune reaction. An inhaled antigen is 
suspected [21, 22], and both mycobacterial proteins and DNA from Proprionibacterium acnes 
have been identified as possible candidate antigens[23]. The causative antigen(s) may not be 
viable bacteria, as patients with sarcoidosis do not demonstrate any increased  risk of 
mycobacterial disease or other opportunistic infections while receiving immunosuppressive 
therapies [24], and patients with sarcoidosis who acquire HIV do not demonstrate progression 
of their underlying sarcoidosis[25]. Conversely, sarcoidosis has been reported in patients with 
HIV infections receiving anti-retroviral therapy, possibly reflecting an immune reconstitution 
inflammatory syndrome [26-28], and in patients receiving biologic agents that promote a Th1 
response,  i.e. interferon treatment [29]. Interestingly, bone marrow and heart transplants from 
patients with sarcoidosis have caused granulomatous inflammation in recipients[24]. A 
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possible explanation for this may be that the eliciting antigen persists in phagosomes, resisting 
degradation.  
An increased incidence among monozygotic twins compared with non-twin siblings, as well 
as variation in disease incidence and disease course between different ethnic groups suggest 
genetic influence on the pathogenesis of sarcoidosis [9]. HLA class II genes have been 
associated with both disease susceptibility and disease phenotypes of sarcoidosis, indicating a 
link to antigen presentation to CD4+ T cells, via binding of the TCR to antigen-loaded HLA 
class-II molecules[30]. Moreover, environmental exposures may produce a granulomatous 
pulmonary disease similar to sarcoidosis. This was demonstrated  in a study on New York 
City Fire Department rescue workers during the first years after World Trade Center attack in 
2001, where an increased incidence of sarcoidosis or a sarcoid-like granulomatous pulmonary 
disease was found[31]. Chronic beryllium disease may give a granulomatous disease of lung 
and skin with high degree of similarities to sarcoidosis. This is a hypersensitivity reaction  in 
beryllium-exposed individuals, and reports have suggested that many patients with chronic 
beryllium disease may be misdiagnosed as sarcoidosis[32]. 
1.3.1 Diagnosis of sarcoidosis 
The diagnosis of sarcoidosis relies on the demonstration of non-caseating granulomas in 
tissue biopsy or aspirate from  lymph node, and exclusion of other causes of granulomatous 
inflammation[33]. The clinical and radiological presentation must also be consistent with 
sarcoidosis, although some patients have atypical findings at presentation, sometimes without 
signs of pulmonary involvement. Thus, sarcoidosis is per definition of unknown etiology, 
excluding similar diseases with known etiology.  
The demonstration of granulomas is not always feasible, due to suboptimal sensitivity of 
transbronchial or bronchial mucosa biopsies, patient preferences or individual cost-benefit 
considerations. In certain subgroups of patients, with presentation suggestive of an excellent 
prognosis, such as Löfgren’s syndrome or Heerfordt’s syndrome (uveoparotid fever), biopsies 
are not considered necessary according to a recent review[13].  
Several other granulomatous diseases may mimic sarcoidosis, such as silicosis, tuberculosis, 
berylliosis[13] or hypersensitivity pneumonitis[34, 35]. The use of BAL cellular differentials 
and lymphocyte phenotypes may be helpful both in identifying patients with an immune cell 
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profile not consistent with sarcoidosis, and to strengthen the diagnosis in cases where biopsy 
specimens fail to confirm granulomas.  
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1.4 HYPERSENSITIVITY PNEUMONITIS 
HP is a syndrome of diffuse and predominantly mononuclear cell inflammation of the small 
airways and lung parenchyma [36, 37]. The inflammation is an immune response to an 
inhaled antigen in predisposed individuals[38], and over 300 antigens, primarily organic in 
nature, have been identified. The disease was described as early as 1713 by Ranazzini da 
Capri, in an influential work on early occupational medicine, in which he stated that ‘Almost 
all who make a living by sifting or measuring grain are short of breath and cachectic and 
rarely reach old age’[36]. 
Although the list of possible causes of HP is extensive, data from a tertiary care referral center 
in the Midwest region of the United States suggest that most cases are caused by avian 
antigens, mycobacterium avium complex in hot tub water, farmer’s lung or household mold 
exposure [39]. In that study the offending exposure was not identified in 25% of the cases. 
HP is commonly classified as acute, subacute or chronic disease, although the usefulness of 
this is debated[40]. Most patients present with symptoms of dyspnea and cough. In the acute 
form, patients often experience a flu-like syndrome 4-12 hours after high level exposure, and 
the offending antigen may be easier to identify than in the chronic form, which often  results 
from continuous, low-level exposure[37, 41].  
On HRCT thorax, subacute HP often presents with patchy or diffuse ground-glass opacities, 
poorly defined centrilobular nodules, mosaic attenuation or air trapping, while reticulation due 
to fibrosis or honeycombing may be seen in patients with chronical disease, often with 
subpleural sparing [42]. Histologically, the classical triad of cellular bronchiolitis, 
bronchiolocentric lymphocytic interstitial pneumonitis and noncaseating granulomas is seen 
in approximately 75% of cases. Areas of organizing pneumonia may also be seen [41, 42]. 
The granulomas in HP are commonly characterized as small or loosely formed, although 
patients with hot tub lung  may have well-formed granulomas[37].  
Patterns on HRCT and pathology specimens from the lung in chronic HP may closely mimic 
those of idiopathic NSIP or IPF [42, 43]. In the updated classification for the idiopathic 
interstitial pneumonias, it was stated that a multidisciplinary discussion is particularly 
important in distinguishing HP from NSIP [8].  Although a set of major and minor criteria for 
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the diagnosis of HP has been proposed [44], there is no universally accepted definition of the 
disease. 
It is still unclear why only a few of those exposed to an antigen develop disease, and why 
some patients heal, while others develop fibrosis[36]. HP is commonly mentioned amongst 
the differential diagnosis in patients with suspected DPLD, and more specific markers of the 
disease are wanted.  
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1.5 BRONCHOALVEOLAR LAVAGE 
Bronchoalveolar lavage was introduced as a research tool by Reynolds and Newball in 1974 
[45]. During the next few years the procedure rapidly gained acceptance and expectations for 
BAL as a diagnostic tool were optimistic[46]. In recent years, the clinical utility of BAL fluid 
cell analysis in patients with suspected DPLD has been a matter of debate and controversy [4, 
6]. In the American Thoracic Society clinical practice guideline from 2012 concerning the use 
of BAL cellular analysis in DPLD [6], it is stated that BAL cellular analysis including total 
and differential counts may be a useful adjunct in the diagnostic evaluation of patients with a 
suspected DPLD. Lymphocyte subset analysis is not recommended as a routine analysis, but 
could be performed if a lymphocytic disease is suspected. On the other hand, the role of BAL 
in respiratory research is unquestionable, and a large part of current knowledge regarding 
inflammatory lung diseases has its origin in research on BALF cells[47]. BAL is considered a 
safe and well tolerated procedure, and can be performed even in critically ill patients with 
adult respiratory distress syndrome [48]. 
Figure 2: Bronchoalveolar lavage fluid cells 
May-Grünwald Giemsa stain. Alveolar macrophages (picture to the left) and three mature lymphocytes (picture 
to the right). Magnification: 1000x. Source: BAL Atlas: © ild care foundation. 
The BAL procedure is described elsewhere[49]. In brief, a flexible fiberoptic bronchoscope is 
introduced via the mouth or nose, and advanced as far as possible into the distal airways to a 
wedged position, where several aliquots of sterile fluid, commonly normal saline, are instilled 
and aspirated through the suction channel of the bronchoscope. The first aliquot of the BALF 
contains more cells from the distal airways, while the subsequent aliquots are thought to 
represent a higher relative fraction of cells from the alveoli. BALF differential cell counts are 
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commonly performed on cytospin preparations stained with May Grünwald/Giemsa and can 
be a useful supplement in the diagnostic work-up of  DPLD[46].  
1.5.1 BALF findings in sarcoidosis and hypersensitivity pneumonitis 
The total cell count and  relative and absolute number of lymphocytes are commonly 
increased in sarcoidosis and HP [50]. Whereas 10-15% of patients with sarcoidosis do not 
have a BAL lymphocytosis at diagnosis, a BAL lymphocyte fraction of <30% makes the 
diagnosis of HP uncertain [6, 51], and the diagnosis of HP is excluded with a normal BAL 
[41]. The lymphocytic cellular pattern in sarcoidosis is dominated by CD4+ T cells typically 
with a CD4/CD8 ratio >3.5 [33]. However, this is not a sensitive marker, as the CD4/CD8-
ratio is normal or even below normal in ~50% of the patients [52]. In addition, the ratio may 
be increased in normal elderly subjects [53]. The BAL lymphocytosis in HP is often 
dominated by CD8+ T cells, resulting in an inverted CD4/CD8-ratio, together with an increase 
in relative numbers of mast cells and neutrophils, and the presence of foamy alveolar 
macrophages[54]. However, considerable overlaps are seen between these two diseases. The 
CD4/CD8 ratio is sometimes increased in HP, and lymphocyte phenotypes may vary with the 
causative antigens [54-56].  
Activated BALF lymphocytes in both sarcoidosis and HP express human leucocyte antigen 
(HLA)-DR [57]. HLA-DR expression on CD8+ lymphocytes has been reported to be lower in 
sarcoidosis than in HP[58], indicating that this may be a useful marker in discriminating 
sarcoidosis from other DPLD. Other lymphocyte subsets can also be identified by 
immunophenotyping with flow cytometry or immunocytochemistry. One of these is the 
Natural Killer T (NKT) cells, which express CD56 and/or CD16, in addition to the T cell 
receptor (TCR). In BALF, a lower fraction of NKT cells has been found  in sarcoidosis 
compared to HP [59]. 
Studies on BAL cells have added immensely to our understanding of the immunopathogenesis 
of sarcoidosis [6, 60, 61], and constitute a safe and well tolerated way to obtain immune cells 
representative of the inflammatory cells found in histological sections of lung biopsy 
specimens[62]. While much of our knowledge on T cell immunology in the lung is derived 
from studies in mice, it is a growing awareness that more emphasis on studies in human 
immune cells is needed to realize the potential benefits of T cell immunology to human 
health[63]. 
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1.6 FLOW CYTOMETRY  
Flow cytometry (FC) is the sine qua non (without which, nothing) of the modern 
immunologist’s toolbox[64]. For detecting antigens expressed intracellularly or on the cell 
surface the technique utilizes the binding of specific monoclonal antibodies conjugated to 
different light-emitting fluorochromes. The advances in both fluorescent molecules and 
modern instrument hardware have made 15-18 color immunophenotyping possible, at speeds 
up to 10000 cells per second. Such high-dimensional, high throughput immunophenotyping 
provides a tool for both broad and in-depth characterization of the cells of the human immune 
system[65]. In addition, the technique allows for sorting of live cell populations on the basis 
of fluorescence and light scatter properties.  
A schematic view on the principles of flow cytometry is presented in figure 1.  
Figur 3: Principles of flow cytometry 
Schematic diagram of a flow cytometer. PMT: photomultiplier tubes; ADC: analogue-to-digital converter. 
"Cytometer" by Kierano - Own work. Licensed under Creative Commons Attribution 3.0 via Wikimedia 
Commons. 
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In FC, the cells are focused into a narrow stream by a rapidly moving sheet fluid, so that they 
pass the laser beams in ‘single file’ (figure 3). The light from the laser beams hitting the cells 
is scattered in the forward or sideward direction (Forward Scatter, FSc and Side Scatter, SSc). 
FSc is an indirect measure of cell size, whereas SSc is related to the intracellular complexity 
of the cell, i.e. granularity. Fluorescently tagged antibodies bound to antigens on the cell 
surface are excited by laser beams at particular wavelengths when the cell is passing by, and 
emitted light from the fluorochromes is detected by photomultiplier tube fluorescence 
detectors. A particular fluorochrome is excited by and emits light within a given range of 
wavelengths. A series of dichroic mirrors and filters split the emitted light, so that each 
detector receives light within a particular range of wavelengths[64]. The light generates a 
voltage pulse in the detector, which is recorded, and data from all detectors are integrated. 
Light emitted from a particular fluorochrome consists of a range of wavelengths and some 
light will spill over into other detectors. This spectral overlap is one of the problems with 
polychromatic flow cytometry. Spectral overlap is dealt with in a computational process 
termed ‘compensation’, which is basically to subtract estimated spectral overlap of light 
recorded in one detector, from recorded signals in other detectors. Individual cells are thus 
characterized by their antigens detected by light scatter properties and emitted light from up to 
18 different fluorescent and specific antibodies.  
Intracellular cytokine staining in FC has made it possible to study the cytokines produced by 
the individual cells after stimulation in a short-term incubation. A protein secretion inhibitor 
is added to secure retention of the cytokines in the cells[66]. This method allows analyzes of a 
large number of cellular functions, including T helper cell subsets, markers of cell viability, 
proliferation or activation states. 
1.6.1 Flow cytometry on BALF cells 
FC has provided an important tool in respiratory research, both in health and disease, such as 
DPLD and sarcoidosis. AM represent the most frequent cell population in the BALF under 
normal condition, often ~90% of the cells.  
The human AM can be identified by their surface expression of CD11c[67], CD14 and MHC 
class II and the size and granularity result in high light scatter properties. Due to their high 
intracellular content of flavo- and metalloproteins, AM display high degrees of 
autofluorescence, i.e. they emit light without being labeled by an antibody-fluorochrome 
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conjugate. When excited by the standard argon laser at a wavelength of 488 nm, the 
autofluorescence of AM peaks at 540 nm, which is close to the wavelength emitted by 
standard fluorochromes like FITC (525 nm) or PE (575 nm)[68]. This must be taken into 
account when designing a panel of antibody-fluorochrome conjugates for 
immunophenotyping of BALF cells. The light scatter properties of BALF cells, contaminating 
erythrocytes and debris are often overlapping, making delineation of lymphocytes by FSc and 
SSc more difficult than in peripheral blood[69]. The lack of standardized protocols or 
guidelines for FC of BALF cells has been a problem, and makes comparison between studies 
difficult[69]. A panel of monoclonal antibodies for identification of leukocyte populations in 
BALF has been proposed [70].  
Figure 4: Gating and visual display of flow cytometry data  
Flow cytometry of bronchoalveolar lavage fluid cells from one patient with sarcoidosis. In the first diagram, the 
forward (FSc) and sidewise (SSc) light scatter properties of the cells are displayed in a scatter-plot. The density 
of cells is coded by color. In the second diagram, CD3+ cells are marked by a red elliptical ring. These cells are T 
cells. For the purpose of this example, the gate is automatically set by a software package in R/Bioconductor 
(See section 7: Future aspects). 
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1.7 THE IMMUNE SYSTEM IN THE LUNG 
Traditionally, the immune system has been classified into the innate and the adaptive immune 
systems. These two systems differ in the specificity of the immune response and the ability to 
generate immunological memory.    
1.7.1 Innate immunity 
The term ‘innate immune system’ refers to the cells and effector mechanisms of our immune 
system that are the oldest, in evolutionary terms, and constitute a system for pathogen 
detection based on molecular patterns shared by many pathogens, and conserved in the 
evolution. The anatomy of the nose and airways, the tight junctions of the epithelial surfaces, 
mucociliary escalator and multiple microbicidal proteins of the airway epithelial fluid are 
important parts of the innate immune system of the lungs as well. An innate immune response 
does not generate immunologic memory, and cannot recognize foreign molecules that do not 
bind to cellular pattern recognizing receptors (PRR), but the response can be immediate, thus 
providing a way to generate inflammation and recruit phagocytes rapidly to counteract a 
potential threat. The interplay between the two legs of the immune system is complex, and the 
division into innate and adaptive immunity may be artificial.  
PAMP and PRR 
Pathogen associated molecular patterns (PAMP) are expressed on the surface of bacteria, 
viruses, fungi or other microbes. PAMP are recognized by PRR expressed intracellularly or 
on the surface of various cells in the lungs, such as epithelial cells, dendritic cells and 
macrophages. Key examples of cell surface and endosomal PRR are the Toll-like receptors 
(TLR), of which 10 are so far identified in humans, so named due to similarities to the ‘toll’-
gene identified in the Drosophilia in 1985. TLRs 1,2,4,5 and 6 are expressed on the cell 
surface, while TLRs 3,7,8 and 9 are expressed in the intracellular compartments. TLR form 
homo- and heterodimers with specificity towards a multitude of PAMP, as well as danger-
associated molecular patterns (DAMP) such as heat shock proteins. An example is TLR2, 
which is expressed widely on AM, DC, lunge epithelial cells and granulocytes [71]. TLR2 
recognizes many bacterial, fungal and viral substances, including the mycobacterial protein 
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Lipomannan. Activation of TLR2 signals induces production of the Th1-driving cytokine IL-
12 in human macrophages through the adaptor protein MyD88 signaling pathway[72].  
Alveolar macrophages 
During the first few days after birth, the lungs and airways are colonized by AM derived from 
fetal monocytes. This cell population develop functional characteristics as an adaptive 
response to cues in the alveolar microenvironment, such as the high oxygen tension and 
surfactants[73], and is maintained by self-renewal throughout life [74]. Lung macrophages 
may be classified as interstitial macrophages, monocyte-derived AM or resident AM, 
although interstitial macrophages are not readily retrieved by BAL [75]. The majority of 
studies on lung derived macrophages do not differentiate between alveolar and airway 
macrophage populations.  
AM have been described as “the masters of contradictory function” [75]. In the steady-state, 
they act as scavenger cells, continuously patrolling and clearing the alveoli and airways for 
debris, apoptotic cells, inhaled foreign particles or microbes and pulmonary surfactant. The 
importance of this function is demonstrated in patients with pulmonary alveolar proteinosis, a 
disease caused by autoantibodies towards the granulocyte-monocyte colony-stimulating factor 
(GM-CSF). These patients have a decrease in number and function of AM, resulting in 
accumulation of surfactant in the alveoli and compromised gas-exchange[76]. Another critical 
function of AM is to tonically suppress the development of inflammation and immune 
responses towards inhaled particles and microbes. Interactions with regulatory ligands on 
epithelial cells or microbes transmit inhibitory signals to the AM through CD200R, TREM2, 
SIRPα, mannose receptor, MARCO and TGF-βR. Under normal conditions, AM produce 
TGF-β and retinoic acid, suppressing T cell activation and skewing the T cell development 
towards regulatory T cells. Due to the lack of co-stimulatory molecules AM function weakly 
as antigen presenting cells (APC).  
However, several mechanisms can override the default anti-inflammatory state of AM. In 
settings with destruction of the airway epithelium, the expression of regulatory ligands may 
be interrupted. Similarly, necrosis, but not apoptosis, liberates pro-inflammatory damage-
associated cellular constituents [75]. In these settings AM may respond to antigens with 
production of pro-inflammatory cytokines, chemokines and lipid metabolites such as IL-8, 
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macrophage inflammatory protein (MIP)-1α, TNF-α, IL-12 or IL-4 and IL-13. In addition, 
circulating blood monocytes are recruited to the lungs under inflammatory conditions, and 
differentiate into inflammatory macrophages[73].  
Dendritic cells 
Much of our knowledge on DC  is based on studies on mice [73]. There are several subsets of 
DC in the lung and airways. DC provide an important link between the innate and the 
adaptive immune system, and are pivotal in priming the response of naïve lymphocytes to 
their specific antigen in peripheral lymphatic tissue. Interestingly, some authors argue that DC 
are in fact cells of the broader mononuclear phagocyte system, without any unique adaptation 
for antigen presentation that is not shared by macrophages [67]. 
Epithelial cells 
Whereas the conducting airways of the lower respiratory tract are lined with columnar, 
ciliated epithelial cells, the epithelial cells of the respiratory bronchioles and alveoli are 
flattened, non-ciliated type 1 pneumocytes. Scattered among these cells in the alveoli are 
surfactant-producing type 2 pneumocytes [73], and dendritic cells with extensions protruding 
between the cells into the lumen are embedded within the epithelium. The epithelial cells are 
important contributors in the homeostatic control of the mucosa. They express PRR [77, 78] 
and can thus sense the presence of microbes [79], and can be induced to produce pro-
inflammatory mediators in response to potential threats [80]. Mediators released by epithelial 
cells may activate and skew the dendritic cell cytokine production and thus the adaptive 
immune response [81]. In one study, an essential role for TLR-signaling in epithelial cells in 
control of pseudomonas aeruginosa pneumonia was suggested [82].  
Granulocytes 
Neutrophils are short-lived phagocytic bone-marrow derived leucocytes that circulate in the 
bloodstream, and serve as the immediate effector arm of the innate immune system[73]. They 
are recruited to the lung by chemotactic factors including leukotriene B4 and IL-8 produced 
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by activated AM and epithelial cells [83], and slowed down in the capillary bed, due to the 
small cross-capillary diameter[84]. Neutrophils express TLR on their surface (lacking only 
TLR3 and 7), and are able to sense the presence of various PAMP [85]. In the air spaces, 
neutrophils phagocyte bacteria and fungi that have been opsonized by complement and 
immunoglobulins, and the microbes are killed in the protected environment of the 
phagolysosome [73]. They are also able to project uncoiled nuclear DNA into the surrounding 
environment as a mean to entrap extracellular bacteria in neutrophil extracellular traps (NET) 
[86]. In addition, neutrophils can produce IFN-γ, TNF-α, and the chemoattractant CXCL-10 
to recruit and modulate activation of NK cells and Th1 cells [87]. Defensins produced by 
neutrophils may also contribute to the modulation of the adaptive immune response via a 
modulatory effect on epithelial cells, T cells and DC [88]. Moreover, the neutrophils produce 
mediators with anti-inflammatory and pro-resolution properties, providing an important 
interface between innate and adaptive immunity [89].  
During the resolution of inflammation, neutrophils undergoing programmed cell death 
(apoptosis) are cleared by macrophages that produce anti-inflammatory cytokines (IL-10 and 
TGF-β), resulting in dampening of the inflammation. The balance between apoptosis and 
necrosis must be tightly regulated, as intracellular content from necrotic cells are recognized 
as DAMP or alarmins by AM, causing the release of pro-inflammatory signals [90]. In the 
adult respiratory distress syndrome (ARDS), neutrophils accumulate in the lung 
microvasculature, interstitium and alveolar space, with disruption of the endothelial-epithelial 
barrier, alveolar damage and pulmonary edema [91]. While the role of neutrophils in the 
pathogenesis in ARDS is still unclear, the reactive oxygen species and other factors released 
by neutrophils may result in tissue damage [92].  
Another granulocyte subset is the eosinophils. These cells are crucial in the killing of 
parasites, and control mechanisms associated with asthma and allergy. They are also capable 
of antigen presentation to T cells [93]. 
1.7.2 Adaptive immunity 
In addition to being highly specific towards the pathogen that induces an adaptive immune 
response, the adaptive immune system has the ability to generate immunological memory[94], 
features that are essential for maintaining immunity to ubiquitous pathogens [95]. The 
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induction of a primary specific immune response takes 7-10 days, while a secondary specific 
immune response can be mounted rapidly, due to the presence of memory cells.  
The lung in healthy individuals contains a small number of lymphocytes, and mostly these 
cells are resident effector-memory T cells, that do not circulate in the peripheral blood [95]. In 
BALF from healthy individuals, less than 10-15% of the cells are lymphocytes [96]. The 
adaptive immune response constitute an interplay of T and B cells with cells of the innate 
immune system, and cells capable of antigen presentation  in the context of MHC class 1 or 2 
play an important role.  
B cells 
B cells, so named because of their site of maturation in birds, the bursa of Fabricius, are 
lymphocytes generated in the bone marrow capable of producing immunoglobulins that can 
recognize almost any foreign antigen that poses a threat to the individual. The enormous 
variety of antigen specificity of the immunoglobulins is generated in a process of genetic 
recombination of gene segments, combinatorial diversity of heavy and light chain matching, 
and somatic mutation of rearranged genes[96]. These cells are important in the protection 
against extracellular bacteria, such as streptococcus pneumonia. To be activated a naïve B cell 
that binds to its antigen is in general dependent on signals from an activated T helper cell that 
recognize the same antigen. 
In the lung, B cells constitute a small fraction of the lymphocytes, with diverse functions, 
serving roles ranging from immunoglobulin production, antigen-presentation and as sources 
of both inflammatory and regulatory cytokines [97, 98]. Lung B cells produce 
immunoglobulins of IgA, IgG or IgM subclasses. IgA antibodies in bronchial secretions bind 
antigens and facilitate their elimination[99]. 
CD8+ (Cytolytic) T cells 
Cytolytic CD8+ T cells are important for recognizing and killing virus-infected cells, and 
major producers of the cytokines IFN-γ, TNF-α and IL-2 [100]. These cells recognize 
peptides from viral antigens presented in the context of MHC class I, and are able to kill 
infected cells directly through several mechanisms. Furthermore, antigen-specific CD8+ T 
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cells are able to recognize and kill cells infected with mycobacterium tuberculosis, and 
provide IFN-γ and TNF-α which are crucial for macrophage activation[100]. 
CD4+ T cells 
In contrast to cytolytic CD8+ T cells, most CD4+ T cells have helper functions, and are 
essential for the generation of an efficient antibody response. The critical role of T helper 
cells in lung immunity is clearly demonstrated by the high incidence of pulmonary infections 
in patients suffering from infection with human immunodeficiency virus[101]. After 
activation in the lymph node, CD4+ T cells may evolve into one of the three major T helper 
cell subsets [96]. Th1 cells produce IL-2, IFN-γ and TNF-α, and are essential in the cell-
mediated immune responses against virus infected cells or intracellular bacteria. Th2 cells 
produce IL-4, IL-5 and IL-13, and are important in the humoral immune response, as well as 
immunity towards parasitic infections. Th2 cells have also been implicated in atopic and 
allergic diseases, and play an important role in the immunopathogenesis of asthma. Recently, 
a subset of T helper cells has been discovered that is characterized by its production of the 
proinflammatory cytokine IL-17. Yet another subset of CD4+ T cells, although not strictly a T 
helper cell is the regulatory T cells, identified by intracellular expression of the transcription 
factor FoxP3. These two subsets of CD4+ T cells have altered the traditional dichotomy of 
Th1 and Th2 cells, and expanded our understanding of immune regulation in health and 
disease[102-105]. In the following sections, we will describe Th17 cells and regulatory T cells 
in more detail. 
Th17 cells 
Th17 cells have an important role in host immunity towards pathogens not adequately taken 
care of by Th1 or Th2 responses, such as extracellular bacteria, fungi and some intracellular 
bacteria requiring a strong inflammatory response [106]. The essential role of Th17 cells in 
lung immunity is clearly demonstrated in patients with hyperimmunoglobulin E syndrome, 
where mutations targeting the STAT3 pathway lead to impaired Th17 cell differentiation and 
function. These patients suffer from recurrent and often severe respiratory infections, 
particularly staphylococcal and fungal, with cutaneous cold abscesses and eczema [107, 108]. 
Th17 cells secrete chemokines that attract neutrophils, and several cytokines are varyingly 
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expressed, including IL-22, IL-17F, TNF-α, GM-CSF and IFN-γ or IL-10. IL-23 secreted by 
DC and AM induces production of IFN-γ by Th17 cells. These cells are reported to be highly 
inflammatory and pathogenic in certain settings [109]. 
Candidate sarcoidosis antigens Mycobacterium tuberculosis and Proprionibacterium acnes 
may both elicit strong Th17 responses [106], although Th17 cells seem to be dispensable for 
protective immunity towards mycobacterial infection [110]. On the other hand, IL-17 recruit 
Th1 cells to the lungs [106], and is required for proper formation of granulomas[111]. In one 
interesting study on mice infected with the intracellular pathogen Francisella tularensis, IL-17 
were reported to induce IL-12 production in lung DC and macrophages, thereby regulating the 
Th1 response, and were required for optimal Th1 immunity [112]. 
Regulatory T cells 
Regulatory T cells are characterized by expression of the transcription factor FoxP3, and have 
a pivotal role in maintaining immune homeostasis and preventing autoimmunity [113, 114]. 
Their importance is demonstrated by the immunodysregulation, polyendocrinopathy, 
enteropathy, X-linked (IPEX) syndrome, which is a severe autoimmune disorder caused by 
mutations in the FoxP3 gene [115]. Since their discovery in 2003 [116, 117], a variety of 
subsets of regulatory T cells have been  identified [118]. Apart from the traditional division 
into thymus-derived natural regulatory T cells (nTreg) and induced (also called peripheral) 
regulatory T cells (iTreg), recent studies have revealed an additional level of complexity. 
Regulatory T  cells express different homing receptors in different anatomical locations, and 
under the influence of inflammatory cues, and can be divided into several distinct subsets, 
with unique functional properties [118]. Much of the current knowledge on regulatory T cells 
is generated from mouse studies. 
1.7.3 The mucosal immune system 
The mucosa of the lungs contains AM and DC within and beneath the surface epithelium 
[119]. Several other cell populations are also present, such as small numbers of mast cells and 
granulocytes, and T cells of effector memory phenotype. The T cell receptor repertoire of 
these cells is unknown [119]. During recent years, the emerging concept of the mucosa 
associated lymphoid tissue (MALT) has increased our insight in how the immune system 
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accomplishes the maintenance of tolerance towards commensal bacteria and inhaled or 
ingested antigens while providing protective immunity against potential harmful microbes. 
The immune system in the lung should be evaluated in this context, and the evolution of the 
adaptive immune system may be a fruitful starting-point. The immune cells of the MALT may 
be key players in the pathology of many chronic diseases, such as asthma, inflammatory 
bowel disease, inflammatory lung disease and COPD. 
The evolution of adaptive immunity 
The mucosal immune system contains the lymphoid tissues associated with the mucosal 
surfaces on the body, holding approximately three-quarters of all lymphocytes in healthy 
individuals. It has been proposed that this may have been the first adaptive immune system to 
evolve in vertebrates, possibly to deal with the vast number of commensal bacteria on the 
mucosal surfaces that co-evolved with the vertebrates [99]. Lymphocyte subsets seem to have 
evolved before the division of the vertebrates into the jawless (agnathans) and jawed 
(gnathostome) lineages, more than 500 million years ago, predating the evolution of both the 
thymus and spleen. These ancestral T and B cells had mechanisms of generation of cell 
surface receptor diversity through some process of somatic gene rearrangement, although the 
adaptive immune system based on the major histocompatibility complex (MHC) and the 
recombination-activating gene (RAG) recombinase enzymes, with T cell receptors (TCR) and 
immunoglobolins (Ig) is unique to the jawed vertebrates (examples are sharks, birds and 
mammals). Common to all the jawed vertebrates is also the thymus, a lymphoid organ derived 
from the embryonic intestine, thought to have co-evolved with the adaptive immune system, 
and the development of highly diverse antigen receptors (i.e TCR and Ig), which created the 
need for a system of negative selection of immune cells to maintain self tolerance[120]. 
Inducible regulatory T cells and Th17 cells may have evolved as gut mucosal immune cells 
with a crucial role in maintaining the immune tolerance towards non-pathogenic commensal 
bacteria, while simultaneously providing an efficient and rapid mechanism for protective 
immunity towards potential threats [121]. In fact, it has been speculated that these cells 
appeared before other CD4+ T cell subsets, Th1 and Th2. An IL-17 ortologue has been found 
in activated lamprey lymphocytes, suggesting that ancestral Th17 cells appeared early in the 
evolution of adaptive immunity [122].  
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Mucosal tolerance 
Subtypes of MALT exist in several tissues containing an epithelial surface, such as the gut-
associated lymphoid tissue, and similarly the bronchus-associated lymphoid tissue (BALT), 
which is found in the larger airways of humans during childhood[119]. Naïve T cells from the 
thymus that encounter their antigens in the mucosa are activated. These cells leave the mucosa 
through the lymphatics, differentiate into effector T cells and recirculate in the bloodstream, 
before they reenter the mucosa due to their expression of homing factors to the tissue in which 
they were primed with antigen. The cytokine micro-environment during initial activation of a 
T cell determines the direction of the immune response to that particular antigen, mainly 
conferred by DC. Different populations of antigen presenting cells, including various subtypes 
of DC as well as AM orchestrate the immune reaction by initiating and controlling the 
activation of antigen-specific T cells [123]. In resting conditions, the DC in the mucosa of the 
respiratory system are biased towards tolerance, and produce IL-10 in response to antigen 
uptake, preventing the development of pro-inflammatory T cells and generating induced 
regulatory T cells expressing FoxP3. Contrary to this, the activation of DC by PRR such as 
TLRs from potential harmful microbes may induce IL-12 production by DC [99].    
Interestingly, in Crohn’s disease, a granulomatous inflammatory bowel disease, there seem to 
be a break-down of tolerance towards commensal bacteria in the intestine, and consequently 
an intense inflammatory T cell immune response in the gut mucosa[99].  
Induction of mucosal tolerance is affected by the route, dose and duration of antigen exposure 
[124]. It is conceivable that these aspects of antigen exposure may be of importance in lung 
inflammatory diseases as well. 
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1.7.4 The immunopathology of sarcoidosis 
The immunologic response of sarcoidosis has been reviewed by Zissel et al.[23]. Sarcoidosis 
is considered as an exaggerated immune response to so far unidentified antigens. BALF 
shows high numbers of activated alveolar macrophages and T cells, whereas in peripheral 
blood lymphopenia is a common finding and T cells express activation markers to a much 
lesser degree [58].  
Alveolar macrophages and Th1cells 
The core of sarcoidosis immunopathogenesis is the presentation of antigen(s) by host 
macrophages in the context of major histocompatibility complex (MHC) class II alleles, 
which are then recognized by antigen-specific CD4+ T cells[9]. Several sequential 
immunological events are involved [23]. Antigen(s) seem to enter the host by inhalation[125], 
and are phagocytosed by APC, predominantly AM or dendritic cells [22]. The pathogenesis 
seems to involve the interplay of antigen, HLA class II and T-cell receptors [126]. It is 
possible that the triggering antigen varies depending on ethnicity, geographic location and 
individual genetic background [22], and different HLA- antigens lead to different disease 
courses. AM in sarcoidosis have excellent APC capacities, due to up-regulated expression of 
HLA class II and co-stimulatory molecules [23], and display a proinflammatory activation 
state and increased expression of adhesion molecules.  
PAMP of microbial antigens can trigger or amplify inflammation[13]. Moreover, serum 
amyloid A in patients with sarcoidosis interact with TLR2 and enhance the production of 
TNF-α, IL-18 and IL-10 (figure 5) [127]. AM produce chemokines including RANTES, mcp-
1, MIP-1α and IL-8, and the proinflammatory cytokines IL-1 and IL-6 and the NF-κB family 
of transcription factors are also up-regulated in sarcoidosis. TNF-α promote microbe killing 
and IL-1β promote granuloma formation[23]. Importantly, IL-12 produced by AM induce and 
maintain the differentiation of Th1 cells, and failure to produce sufficient IL-12 may result in 
incomplete Th1 differentiation[23]. 
T cells in sarcoidosis exhibit a restricted T cell receptor repertoire, shown to be consistent 
with oligoclonal expansion, strongly suggesting an antigen-specific response[24]. The Th1 
transcription factor STAT1 is up-regulated, and most CD4+ T cells produce IFN-γ, which 
activates AM and enhance phagocytosis and oxidant production, and IL-2. IL-15 and TNF-α 
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from AM in synergy with IL-2 stimulate T cell proliferation[9], granuloma formation and 
maintenance. In addition, the Bcl-2 family of genes are up-regulated in sarcoidosis, consistent 
with a prosurvival and anti-apoptotic profile for activated T cells [23].  
Granulomas 
The generation of granulomas is considered to be an immune response to foreign material or 
microbes that are poorly degradable or persisting, as a way of preventing antigen 
dissemination and further tissue damage[24]. AM play a key role in the control of 
granulomatous inflammation, and is the cell type that interact most frequently with both the 
infectious agent and other immune cells within the granulomas[128]. In the granulomas of 
tuberculosis, cells and mediators that promote bacteria killing must be controlled to prevent 
tissue damage. AM and regulatory T cells exerting anti-inflammatory effects seem to be 
beneficial to the control of infection, possibly via regulatory effects on effector T cells [128]. 
Within the sarcoidosis granulomas CD4+ T cells are scattered, while CD8+ T cells and B cells 
can be seen in the periphery.  
Figure 5: Hypothesis to the pathobiology of 
sarcoidosis. 
In the acute-phase response towards the offending 
microbe (according to this hypothesis a mycobacterial 
infection) serum amyloid A (SAA) is induced (1). 
Mycobacterial proteins (mKatG) (2) are trapped 
within aggregates of misfolded SAA that serve as a 
nidus for granuloma formation (3). SAA can be 
released from graunulomas, leading to an 
amplification of the Th1-response through 
interactions with Toll-like receptor (TLR)2 (4). The 
granulomatous inflammation results in remission 
after successful clearance of the inciting antigen and 
SAA (5), or chronic inflammation and fibrosis (6). 
Reprinted with permission of the American Thoracic 
Society. Copyright © 2014 American Thoracic 
Society. Chen ES et al., 2010 Serum amyloid A 
regulates granulomatous inflammation in sarcoidosis 
through Toll-like receptor-2, Am J Respir Crit Care 
Med. 15;181(4):360-73. 
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Other immune cells 
The role of IL-17 producing T helper cells and FoxP3+ CD4+ T cells in sarcoidosis has not 
been fully clarified[19]. Increased Th17 cell fractions in BALF and the granulomas on tissue 
specimens have been reported [129]. Cell subsets producing TNF-α or IFN-γ in addition to 
IL-17 have been found in inflamed tissue in various conditions[130-132], and these cells are 
believed to have distinct effector functions[133]. Peripheral blood Th17 cells in sarcoidosis 
were reported to contain an augmented fraction of IFN-γ+ cells [134]. The reports on 
regulatory T cells in sarcoidosis are differing. Augmented numbers of FoxP3+ CD4+ T cells 
are found in and around granulomas [135], while in BALF both increased [136] and decreased 
frequencies [137] have been reported. Regulatory T cells and Th17 cells share developmental 
and functional links [121, 138], and in some autoimmune diseases an imbalance of these cell 
subsets has been suggested [139-142].  
Less attention has been offered to the cytolytic CD8+ T cells. These cells release TNF, IFN-γ 
and IL-2, adding to the overall Th1 cytokine release in sarcoidosis. In addition, CD1d-
restricted NKT cells, a subset with immunoregulatory properties has been reported in 
diminished numbers in patients with sarcoidosis without Lõfgren's syndrome [143]. 
Resolution or persistence  
Resolution is thought to be the result of a successful immune response, with removal of the 
eliciting agent and a subsequent down-regulation of the immune processes involved by TGF-β 
and regulatory T cells. However, the contribution of regulatory T cells in sarcoidosis is 
equivocal. In theory these cells may dampen the inflammatory response, which could be 
considered beneficial during the resolution phase. On the other hand, fibrotic sarcoidosis may 
also be the result of an insufficient Th1 immune response. Incomplete removal of the eliciting 
antigen may result in persistence of the granulomas, and ongoing granuloma formation [23]. 
Mechanisms leading to fibrotic lung disease might include generation of a pro-fibrotic 
alveolar macrophage phenotype, M2 AM, possibly promoted by IL-10 and/or IL-13 [19]. M2 
AM release the pro-fibrotic chemokine CCL18. The lack of a sufficient Th1 or M1 activation 
may result in a shift from classically to alternatively activated AM (M2), and might be 
responsible for the fibrotic outcome in sarcoidosis[23]. To increase our understanding of the 
processes leading to fibrotic sarcoidosis is a key priority[19]. 
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2 AIMS
2.1 OVERALL AIMS 
To investigate and identify BALF profiles and lymphocyte phenotypes that can increase the 
diagnostic accuracy of BALF in sarcoidosis and HP. 
To explore the frequency and balance of regulatory T cells and Th17 cells in sarcoidosis and 
healthy control subjects. 
2.2 SPECIFIC AIMS FOR THE INDIVIDUAL PAPERS 
Paper 1 
To compare fractions of BALF HLA-DR+ CD8+ T cells and NKT cells between patients with 
sarcoidosis and HP, to identify typical BALF cellular profiles and phenotypes that may be 
used to discriminate HP and sarcoidosis. 
Paper 2 
To evaluate whether the inclusion of the lymphocyte subsets HLA-DR+CD8+ T cells and 
NKT cells increases the diagnostic accuracy of BALF investigations in a diagnostic model of 
sarcoidosis. 
Paper 3 
To investigate the fractions of FoxP3+ CD4+ T cells, Th1, Th17, and IFN-ߛ+ Th17 cells in 
BALF in patients with sarcoidosis compared to healthy controls, and to assess the hypothesis 
that the balance between these subsets is skewed. To correlate the frequencies of these subsets 
with the radiological stage in patients. 
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3 GENERAL MATERIAL AND METHODS
3.1 STUDY POPULATION 
For all the papers the diagnosis of sarcoidosis was considered certain if clinical presentation 
and thoracic imaging were consistent with pulmonary sarcoidosis and there was non-caseating 
granulomas in endobronchial or transbronchial biopsy specimens or from endobronchial 
ultrasound-guided transbronchial needle aspirations of enlarged hilar or mediastinal lymph 
nodes [33]. Histological demonstration of granulomas was not required for patients presenting 
with Löfgren’s syndrome, defined as bilateral hilar lymphadenopathy with fever, erythema 
nodosum and/or ankle arthritis. Patients on systemic corticosteroids at the time of 
bronchoalveolar lavage were not included. Patients were stratified  by findings on chest 
radiograph at presentation into stages 0-4, according to Scadding[144]. Exclusion based on 
missing data, sarcoidosis with concomitant cancer, immunosuppressive therapy or uncertain 
diagnosis was decided without knowledge of the results of the flow cytometry analyses.  
More detailed descriptions of the inclusion and exclusion criteria are provided in the 
individual papers. 
Paper 1 and 2 
The study population was generated from 226 patients investigated with flow cytometric 
analysis of BALF samples in our clinic between September 2007 and June 2010, where 
DPLD was a possible differential diagnosis after initial clinical and radiological evaluation. 
After investigative work-up, patients were grouped on the basis of the diagnosis reached by 
the attending respiratory physician into sarcoidosis (N=76) and non-sarcoidosis. Patients with 
a clinical diagnosis of sarcoidosis who did not fulfill the diagnostic criteria described above 
for sarcoidosis were excluded, yielding a study-population of sarcoidosis (N=51) and non-
sarcoidosis (N=132) for paper 2. Eleven patients presented with Löfgren’s syndrome. 
As some time had elapsed before data analysis for the study in paper 1, we were able to 
extend the inclusion period for this study until September 2012. From this cohort 146 patients 
were given a diagnosis of sarcoidosis or HP. Eighty-tree patients with sarcoidosis and 10 
patients with HP fulfilled the respective diagnostic criteria, and 53 patients were excluded 
(uncertain diagnosis: N=35; active cancer: N=7; missing data: N=1; immunosuppression: 
Paper III
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N=10). Sixteen patients presented with Löfgren’s syndrome. Patients with HP had at least 4 of 
the major criteria and 2 of the minor criteria as  suggested by Schuyler et al.[44].  
Paper 3 
For the third paper, patients investigated with bronchoalveolar lavage between November 
2010 and September 2012 for possible DPLD were eligible for inclusion in the study if they 
had a BALF lymphocyte fraction greater than 5% of the leucocytes and were not receiving 
systemic therapy with corticosteroid or methotrexate. We included 30 patients with 
sarcoidosis and 18 patients with other DPLDs. Five patients presented with Löfgren’s 
syndrome. Investigation of intracellular expression of IL-17A and IFN-γ was performed in 23 
patients with sarcoidosis (3 patients with Löfgren’s syndrome) and 11 patients with other 
DPLD.
Eight male and 7 female healthy non-smoking control subjects with no history of allergy, 
asthma or other lung diseases were recruited by advertising on the hospital web-site. All had 
normal chest radiography and CO diffusing capacity. The FEV1/FVC ratio was below 0.7 in 
one subject (0.67). A second subject had a FEV1 of 76 % of predicted value. 
For papers 1 and 2, the regional ethics committee (REC Central, Norway) did not consider the 
study to require ethical approval, because it was regarded to be a routine clinical quality 
control investigation and in accordance with the amended Declaration of Helsinki (Ref. no.: 
2009/909-2). For paper 3, written informed consent was obtained from all subjects, and the 
study was approved by the Regional Ethics Committee (Ref.nr.: 2010/1939-4). 
49 
3.2 BRONCHOALVEOLAR LAVAGE 
BAL was performed in accordance with recommendations [49]. The lavage site was guided 
by evidence of parenchymal pathology on HRCT, and if indifferent, lavage was performed in 
the right middle lobe. Local anesthesia with lignocaine and intravenous sedation with 
midazolam and alfentanyl was given, and with the bronchoscope in a wedged position in a 
segmental bronchus, 2-3 aliquots of 60 ml phosphate-buffered saline were instilled, and 
retrieved by applying gentle suction. The first fraction was used for microbiological analyses 
when appropriate, while the second and third fractions were pooled and filtered through nylon 
gauze (paper 1and 2) or a Falcon Cell strainer with 100 μm nylon mesh (paper 3) and stored 
at 4° C until processing.  
Total and Differential Cell Counts.  
The total cell count was made by ADVIA 120 Hematology System, and differential cell 
counts on a minimum of 300 cells were performed on Cytospin slides stained with May-
Grünwald/Giemsa. 
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3.3 MITOGEN STIMULATION OF LUNG IMMUNE CELLS (PAPER 3) 
BALF cells were stimulated within 4 hours of collection and fixed according to the protocol 
in the Human Th17/Treg phenotyping kit (BD Biosciences). Firstly, the cells were incubated 
for 5 hours in a medium of Roswell Park Memorial Institute medium (RPMI) with 10 % Fetal 
calf serum (FCS) with addition of the mitogens ionomycin at 1μg/ml and phorbol-12-
myristate-13-acetate (PMA) at 50 ng/ml. A protein transport inhibitor was added to prevent 
protein transport to the extracellular space. Cells were also cultured in medium without 
mitogens, as negative control. Secondly, the cells were fixed using the BD FoxP3 buffer set. 
Lastly, the cells were suspended in a medium of 90% FCS and 10% dimethyl sulfoxide and 
stored for <6 months at −80° C until batch processing.  
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3.4 FLOW CYTOMETRY 
Flow cytometry was performed with a FACS Canto I flow cytometer with FACS DIVA 
software. A minimum of 10.000 cells or 50 000 cells were analyzed in tubes investigating 
only surface antigens or intracellular antigens, respectively. 
For paper 1 and 2, tubes containing 0.5-1.0 x 106 BALF cells per tube were incubated for 15 
minutes with antibodies against surface antigens, and the cells were then washed twice in 
phosphate buffered saline with 0.1 % bovine serum albumin. 
For paper 3, unstimulated cells were incubated with permeabilization buffer (BD 
Biosciences), and then stained with antibodies to surface antigens and intracellular FoxP3+. 
The mitogen-stimulated cells and unstimulated controls, were thawed, permeabilized and then 
stained with antibodies to surface antigens and intracellular IL-17 and IFN-γ.  
Details of the antibody panels are listed in Table 1. 
Table 1: Flow cytometry antibody panel 
Tube Antibody conjugates 
FITC PE PerCP-Cy5.5 PE-Cy7 APC APC-Cy7 
Paper 1 and 2 
1 Isotype control Isotype control Isotype control Isotype control 
2 CD8 CD4 HLA-DR CD3 
3 CD3 CD16 and CD56 CD45 CD19 
Paper 3 
1 Isotype control Isotype control Isotype control Isotype control Isotype control CD45 
2 CD8 CD4 HLA-DR CD3 
3 CD4 FoxP3 CD8 CD27 CD39 CD25 
4  CD4 IL-17A CD8 IFN-γ FoxP3 CD3 
FITC: Fluorescein isothiocyanate, PE: phycoerythrobilin, PerCP-Cy5.5: Peridinin chlorophyll protein with 
cyanine dye (Cy5.5), APC: Allophycocyanin. 
Gating 
Lymphocytes were identified by their low side- and forward scatter. 
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For paper 1 and 2, lymphocytes were also confirmed to be CD45+ (tube 3). Gates 
discriminating HLA-DR+ and HLA-DR- lymphocytes were generated from the isotype control 
tube. NKT cells, in this study defined as CD16/CD56+ CD3+ lymphocytes, were gated by 
visual comparison to the dominating population of CD16/CD56- CD3+ lymphocytes.  
For paper 3, regulatory T cells were defined as FoxP3+ CD4+ lymphocytes (tube 3). In the 
tube with mitogen-stimulated cells T cells were identified as CD3+ lymphocytes and further 
gated by expression of CD4 and CD8 into the two main subsets. Gating of CD4+ T cell 
subsets is shown in figure 5. Unstimulated cells were used as negative controls. 
 
Figure 6: Regulatory T cells, Th1, Th17 and IFN-γ+ Th17 cells in bronchoalveolar lavage fluid 
Gating of CD4+ T cell subsets in a healthy control subject (upper panel) and a patient with sarcoidosis (lower 
panel). The T cell subsets are defined as follows: Th1 cells: IFN-γ+ CD4+; Th17 cells: IL17+ CD4+; regulatory T 
cells: FoxP3+ CD4+ and IFN-γ+ Th17 cells: IFN-γ+ IL-17+ CD4+. Gates for IL17 and IFN-γ were set according to 
unstimulated CD4+ T cells. 
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3.5 STATISTICAL ANALYSIS 
 
Group comparison of continuous data was done with Kruskal-Wallis test in papers 1 and 3, 
and Mann-Whitney U test in paper 2. If a significant difference was found with Kruskal-
Wallis test, post hoc analyses were performed with Mann-Whitney U test (Bonferroni 
correction for multiple comparisons was deployed in paper 1). Categorical data were analyzed 
with Fishers exact test in paper 1 and Pearson chi-squared test in papers 2 and 3. In paper 3, 
correlation was investigated with Spearman’s rank correlation test. A p-value of < 0.05 was 
considered to be statistically significant. 
Statistical analyses were done in R: A Language and Environment for Statistical computing 
(R Core Team, R Foundation for Statistical Computing, Vienna, Austria).  
In paper 2, we evaluated the diagnostic accuracy of BALF investigations in a diagnostic 
model of sarcoidosis with and without the inclusion of the BALF lymphocyte subsets HLA-
DR+CD8+ T cells and NKT cells. Essentially, we sought to design a prediction model with 
which clinicians can calculate the probability of sarcoidosis based on variables obtained by 
BALF investigation.  
In our prediction model, we used age, sex, total cell concentration, eosinophils and 
neutrophils in differential counts and proportion of lymphocytes[145] and CD4/CD8-ratio 
from flow cytometry analyses, based on expected clinical relevance of these variables [46, 57, 
146]. Model selection from these candidate variables was done with backwards stepwise 
elimination based on the Akaike information criterion[147]. The variables neutrophils and 
total cell concentration did not significantly improve model fit, and were excluded from the 
model.  
With the knowledge of the final diagnoses in the individual patients in the study population 
(sarcoidosis or non-sarcoidosis), binary logistic regression was used to estimate a function for 
the likelihood ratio (LR) of sarcoidosis, based on the variables in our prediction model. LR is 
the probability of seeing a certain data set in a patient with a given disease divided by the 
probability of seeing the same data set in a patient without the disease[148]. For the individual 
patients, the posttest probability of sarcoidosis could then be calculated as: 
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The pretest probability was defined as the prevalence of sarcoidosis in the study population 
(51/183).  
Sarcoidosis often presents in younger adults, but a second peak in incidence rates is seen in 
older women[149]. Thus, the probability of sarcoidosis may not vary linearly with the 
variable ‘age’, and similar relations may be found in other variables as well. Fractional 
polynomials, a tool in logistic regression modeling, was used to find the simplest (if any) non-
linear transformation of continuous variables that could increase model fit [147], and by 
transformation of the variables age and proportion of lymphocytes model fit was significantly 
increased.  
The posttest probability of sarcoidosis for each individual patient was then calculated from the 
resulting prediction model (the basic model), and from a final model also including the 
variables HLA-DR+CD8+ T cells and fraction of NKT cells. The diagnostic accuracy of the 
models can be estimated as the area under the Receiver operating characteristic (ROC) curves 
[150, 151], which are plots of sensitivity versus 1-specificity at different thresholds for a 
positive test result, and represent a measure of the diagnostic accuracy of a test. 
In lack of a new dataset to validate the model, we performed an internal validation, in which 
we randomly selected half of the patients in the study population for estimation of the model 
coefficients, and then tested the diagnostic accuracy of the resulting model in the other half 
[152, 153]. This procedure was repeated 1000 times in both prediction models, and the 
median value of the area under the ROC curve with 95% confidence interval was calculated 
for each model, representing a more robust estimate of the diagnostic accuracy of the models. 
The logistic regression models were compared with the likelihood-ratio test, and a non-
parametric approach to the analysis of areas under correlated ROC curves described by 
DeLong et al [154] was used to compare the areas under the ROC curves.  
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4 MAIN RESULTS AND DISCUSSION 
4.1 BALF LYPHOCYTE PHENOTYPES IN SARCOIDOSIS AND HP 
(PAPER 1) 
We investigated BALF cellular profiles and T cell phenotypes in patients with a confident 
diagnosis of sarcoidosis (N=83) and HP (N=10), in search of diagnostic markers. In our 
laboratory, BALF lymphocyte phenotyping has included HLADR expression and 
identification of NK cells (to count for non-T non-B cell lymphocytes), thereby also providing 
quantification of T cells expressing NK cell markers (termed NKT cells).  
Lymphocytes and eosinophils fractions in BALF were higher in patients with HP compared to 
sarcoidosis [median (IQR): 69 (66-74) % versus 31 (21-52) %, p=0.0001 and 4 (1-7) % versus 
0 (0-1) %, p=0.008], while fractions of alveolar macrophages were markedly higher in 
patients with sarcoidosis compared to HP [57 (39-75) % versus 21 (15-28) %, p<0.0001]. The 
expression of HLADR on CD4+ T cells was higher in patients with HP compared to 
sarcoidosis [89 (81-93) % versus 69 (60-79) %, p= 0.0002]. Both NKT cells and the fraction 
of HLADR+ CD8+ T cells were strikingly augmented in patients with HP compared to 
patients with sarcoidosis and HC, while the CD4/CD8-ratio was higher in sarcoidosis (figure 
6). The combination of high fractions of NKT cells and HLA-DR+ CD8+ T cells seem to 
discriminate patients with HP from sarcoidosis very well, as shown in figure 7d. A typical 
example of flow cytometry dot plot for expression of NK cell markers on T cells and 
histograms denoting HLADR+ populations of CD4+ and CD8+ T cells in a patient with HP is 
given in figure 7e. 
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Figure 7: NKT cells and HLADR+ CD8+ T cells in BALF 
Panel a-c): CD4/CD8- ratio, fractions of HLADR+ CD8+ T cells and NKT cells in BALF in patients with 
sarcoidosis, hypersensitivity pneumonitis (HP) and healthy control subjects (HC). d) Scatterplot of fractions of 
NKT cells and HLADR+ CD8+ T cells in individual patients. In this plot these two markers used in conjunction 
seem to discriminate between the two diagnoses. e) Example of flow cytometry diagrams from a representative 
patient with hypersensitivity pneumonitis. 
Our findings of higher NKT cell fraction of BALF lymphocytes in HP is in agreement with a 
study by Korosec et al., in which BALF NKT cells from patients with HP (N=17) and 
sarcoidosis (N=57) was investigated [59]. They reported NKT cells as fractions of 
lymphocytes, while we reported NKT cells in fractions of leucocytes, to minimize the impact 
of noise in the flow cytometry gates in patients with low lymphocyte counts. However, 
recalculation of the NKT cell fractions as fractions of lymphocytes did not alter the principal 
findings. Also consistent with the previous study, we did not find significant difference in the 
frequency of traditional NK cells (CD3-CD16/56+ lymphocytes). In a recent study increased 
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fractions of NKT cells was found  in patients with COP, but not in HP, compared to controls 
[155]. However, the control group in that study was generated from patients referred for 
investigations for chronic cough. We also provide a comparison with NKT cell fractions in 
HC, which are lower than in sarcoidosis (see figure 6c). NKT cells were for the purpose of 
this study defined as CD16/56+ CD3+ lymphocytes, in line with the initial description of T 
cells expressing NK cell markers. In the study by Korosec et al., this cell subset was identified 
as mainly CD8+, and expressing unbiased αβ-TCR, while only a small percentage of NKT 
cells expressed the invariant CD1d-restricted TCR[59]. Accordingly, NKT cells as defined in 
both studies chiefly correspond to cells that are recently termed NKT-like cells[156]. These 
cells might vary widely in function, and are reported to produce IFN-γ, and not IL-4[156], and 
may include conventional T cells with upregulated NK cell markers[157]. It is conceivable 
that these cells are not functionally linked to the CD1d-dependent NKT cells. One study on 
human CD8+ T cells expressing NK cell markers CD56 and/or CD57 denoted that these cells 
produced large amounts of IFN-γ when stimulated with IL-2, IL-12 and IL-15, and displayed 
anti-tumor and cytotoxic activity dependent on the perforin/granzyme pathway[158].   
The increased expression of HLADR in CD8+ T cells in HP observed in the current study is 
also in line with a previous report[58]. In that study, expression of several activation markers 
was investigated in BALF T cell subsets in patients with sarcoidosis, HP and HC. 
Lymphocytes in BALF from both patients and HC were found to display higher expression of 
markers of activation (as reported by others[159]), including HLA-DR, compared to 
lymphocytes in peripheral blood. Expression of HLA-DR was higher in CD8+ T cells in 
BALF from patients with HP compared to sarcoidosis. We found no correlation of HLA-DR 
expression on CD8+ T cells to radiologic stage in sarcoidosis, as they reported.  
HLA-DR is a MHC class II molecule and has an important function on the cell surface of 
antigen presenting cells and B cells presenting antigens to naïve T cells. HLA-DR has been 
known to be expressed on activated T cells for several decades, perhaps somewhat surprising, 
as T cells do not normally function as antigen presenting cells. In this context, HLA-DR is 
thought to play a role in regulating or limiting a specific T cell response [160]. Cross-binding 
of HLA-DR molecules induce protein tyrosine phosphorylation and increased cytoplasmic 
second messengers, and upregulate expression of adhesion molecules [160]. Increased 
expression of HLA-DR on CD8+ T cells has been observed in autoimmune diseases, human 
immunodeficiency virus infections and in normal aging [161]. Activated T cells in Th1-
responses produce IFN-γ, and are essential in granuloma formation, a characteristic of both 
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HP and sarcoidosis[162]. Activated CD8+ T cells are cytolytic, and are crucial in the host 
defense towards intracellular pathogens, and in killing tumor cells. The reasons for the 
expansion of cells of this phenotype in HP are unclear, and although many kinds of fungi and 
bacteria have been identified as environmental agents in HP [37], they are not present as 
virulent pathogens requiring a cytolytic immune response. Thus, a further exploration of the 
function, phenotype and cytokine profile of these cells in HP may be justified. 
We are not aware of any prior reports on the use of these two markers in discriminating HP 
from sarcoidosis. In the present study, the number of patients with HP is not sufficient to 
investigate the diagnostic accuracy of HLADR status on CD8+ T cells and fractions of NKT 
cells in HP. Furthermore, this combination of lymphocyte phenotypes may not be specific for 
the diagnosis HP. Increased NKT cell fractions have been reported in COP, and these 
lymphocyte phenotypes should also be studied in patients with other differential diagnoses to 
HP, such as NSIP, DPLD associated with medication or rheumatic disease or infectious 
diseases mimicking HP.  However, as demonstrated in figure 6d, the combination of high 
fraction of NKT cells and a high degree of expression of HLADR on CD8+ T cells are 
strongly suggestive of HP rather than sarcoidosis, and if a patient has BALF findings not in 
agreement with the suspected diagnosis, a careful reevaluation may be justified. 
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4.2 BALF IN DIAGNOSIS OF SARCOIDOSIS (PAPER 2) 
In our clinic there has been a tradition for the use of BALF investigations in research (for 
example [163, 164]) and in the diagnostic work-up of sarcoidosis, HP and suspected DPLD. 
Lymphocyte phenotyping with flow cytometry was performed with four colours from 
September 2007, and extended to six colours in October 2010. Due to the controversy of the 
usefulness of BALF investigations in DPLD, and lymphocyte phenotyping in particular, we 
designed a study on the diagnostic accuracy of BALF in sarcoidosis, by far the most common 
entity of DPLD in our clinic. We also included the patterns of HLADR expression and 
fractions of NKT cells presented in paper 1, to see if these lymphocyte phenotypes could 
increase the diagnostic accuracy of BALF in sarcoidosis. 
Table 2: Differential counts and lymphocyte phenotypes 
Characteristic Sarcoidosis 
(N=51) 
Non-sarcoidosis 
(N=132) 
P 
Differential  
cell count 
Total cell count (x106/ml) 0.19 (0.13-0.29) 0.26 (0.16-0.47) 0.002 
Neutrophils (%) 3 (1-10) 7 (2-32) 0.001 
Eosinophils (%) 0 (0-1) 1 (0-4) 0.015 
Flow  
cytometry 
Lymphocytes, (%) 37.9 (20.5-57.0) 13.6 (5.5-46.9) <0.0001 
CD4/CD8 ratio 3.8 (2.1-8.9) 1.5 (0.7-2.8) <0.0001 
NKT cells (% ) 0.27 (0.12-0.56) 0.10 (0.01-0.62) 0.007 
HLA-DR+ CD4+ T cells  (% of CD4+) 65.6 (59.1-77.1) 71.7 (54.0-83.3) 0.238 
HLA-DR+ CD8+ T cells  (% of CD4+) 37.1 (27.6—48.8) 50.0 (33.3-71.6) 0.0003 
Data presented as median (IQR). Numbers represent fractions of leucocytes, unless otherwise stated. 
Patients with sarcoidosis had higher fractions of lymphocytes and CD4/CD8-ratio compared 
to non-sarcoidosis patients, while neutrophils, eosinophils and HLA-DR+ fractions of CD8+ T 
cells were higher in the latter group. Although NKT cell fractions were marginally higher in 
patients with sarcoidosis, this was not so in patients with elevated lymphocyte fractions. In 
patients with lymphocyte fraction above 15 %, NKT cell fractions were lower in sarcoidosis 
(median: 0.31 versus 0.73, p=0.004).  
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Interestingly, among 18 patients with NKT cell fractions above 2.0% of the leucocytes, five 
patients had HP, three had lymphoma/chemotherapy and/or pneumocystis jirovecii (one of 
which had HIV and pneumocystis infection), one had methotrexate-induced DPLD, one had 
cytomegalovirus pneumonia, one had sarcoidosis, two had cancer and four patients had 
another entity of DPLD. The presence of NKT cells, which are commonly thought to have 
high anti-viral and anti-tumor activity in patients with cancer or intracellular infections, is not 
surprising. Patients with suspected DPLD associated with drugs (chemotherapy or 
methotrexate) also had high expression of HLADR on CD8+ T cells, similar to patients with 
HP (see section 4.1). This may reflect the case that drug-induced DPLD in some cases may be 
hypersensitivity reactions[165].  
 
Lymphocyte phenotypes increase diagnostic accuracy of BALF in sarcoidosis  
As described in section 3.5, we used logistic regression to estimate a function for the 
likelihood ratio of sarcoidosis based on selected BALF variables, age and sex. The aim was to 
design a prediction model to be used as an adjunct in diagnosing DPLD and sarcoidosis, and 
evaluate the diagnostic accuracy of this model. Selection of variables in a prediction model is 
performed with the aim to identify good predictors of an outcome or a diagnosis (in this case 
sarcoidosis). In general, the simpler model may be the better in clinical use, however the 
model structure and number of variables are less critical in a prediction model compared to an 
explanatory model[166]. Even so, knowledge of the subject should guide variable 
selection[147]. The resulting model (basic model) was compared with a final model also 
including NKT cell fraction and HLA-DR+ fraction of CD8+ T cells. The resulting function 
for LR for the final model was: 
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Knowing LR, the predicted probabilities of sarcoidosis for the individual patients were 
calculated by the formula shown in section 3.5. The results are displayed in figure 7a. ROC 
curves were generated and area under the curve calculated to assess the diagnostic accuracy of 
both models (figure 7b).  
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Figure 8: Predicting sarcoidosis from bronchoalveolar lavage fluid data 
Panel a): Predicted probability of sarcoidosis using the final model for the individual patients in the study 
population, grouped according to the true diagnosis. Patients with Löfgren’s syndrome are represented by red 
dots. The dashed horizontal line demarks a cutoff of 25% for discriminating a positive versus negative test. This 
cutoff would have yielded 4 false negative and 27 false positive patients. b) ROC curves for the basic (black 
line) and final (red line) model. 
 
The area under the ROC curve for the final model was significantly higher compared to the 
basic model: 0.937 (95% CI: 0.902-0.973) versus 0.898 (0.851-0.945), p = 0.008, see figure 
7b, and had significantly better fit to the data (p<0.0001, likelihood ratio test). Thus, the 
addition of NKT cell fractions and HLADR+ fraction of CD8+ T cells increases the diagnostic 
accuracy of BALF in sarcoidosis.  
Assessing the diagnostic accuracy of a given test critically depends on the selection of the 
study population. Patients with sarcoidosis (N=51) were confirmed to fulfill diagnostic 
criteria. In contrast to this, the non-sarcoidosis group (N=132) also included patients without a 
confident diagnosis, as a diagnostic model should be able to discriminate patients with 
sarcoidosis from these patients as well. In this study we retrospectively included patients with 
suspected sarcoidosis or DPLD prior to BALF investigations. An improvement of the study 
design might be to include prospectively only patients with suspected or possible sarcoidosis. 
However, to do this retrospectively without introducing biased patient selection may prove 
challenging. The common failure to reach a confident diagnosis in patients with DPLD is an 
obstacle, and excluding patients with uncertain diagnoses also means excluding patients in 
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which supplementary diagnostic tools such as BALF investigations are most needed. 
Conversely, it is possible that patients with sarcoidosis included in paper 2 (and patients with 
HP in paper 1) may be those with more typical presentation, clinical and radiological findings, 
and easily detectable granulomas. Details on the heterogeneous group of non-sarcoidosis 
patients are given in paper 2.    
The preferred study design to investigate the diagnostic accuracy of two prediction models 
would be to select the variables and estimate model coefficients in one half of the study 
population and test the performance of the models in the other half. Any assessment of 
retrospective fit ‘uses the data twice’[166], and may overestimate the diagnostic accuracy 
[167]. However, the number of patients is a limiting factor in a logistic regression model, and 
we did not have a sufficient number of patients to split the dataset in two. The approach of 
repeated random subsampling is a method of internal validation, and provides a more realistic 
estimate of the diagnostic accuracy. The median area under ROC curve after 1000 repeated 
random subsampling was 0.898 versus 0.866 in the final and basic models, respectively. 
Nevertheless, these corrected estimates are also biased by the selection of variables in the 
model, which was based on data from all patients. Thus, an external validation of our model 
in a prospective setting could further strengthen our results.  
Logistic regression has been used previously in studies on BALF in diagnosis of sarcoidosis 
and other DPLD [168-170]. These studies conclude that BALF investigations are helpful in 
discriminating sarcoidosis from other DPLDs or infectious disorders. The two studies by 
Drent et al. are restricted to patients with confirmed diagnoses of sarcoidosis, HP or idiopathic 
pulmonary fibrosis, and in the later study [169] extended to include patients with infectious 
disorders. It is uncertain how well these results translate to a population of suspected DPLD 
or sarcoidosis, which is a more common clinical situation. The other study [168] investigates 
BALF lymphocyte fractions and CD4/CD8-ratio. In our study, two additional lymphocyte 
subsets are added in the model, significantly increasing diagnostic accuracy.  
Some patients have been wrongly classified by the final prediction model, particularly 4 
patients with sarcoidosis, who had a predicted probability of less than 25%, and 5 patients 
who did not have sarcoidosis, and was scored by the prediction model as having >70% 
probability of sarcoidosis. Two of the former patients had lymphocyte counts below 10%, 
whereas two in the latter group had CD4/CD8-ratio above 10, indicating that the presence of 
particular BALF findings may have strong influence on the predictions by our model.   
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This study establishes that BALF investigations including lymphocyte phenotyping can be 
used as a supplementary diagnostic tool in sarcoidosis, and indicate that similar prediction 
models based on BALF data may be developed for other diagnoses, such as HP. As 
demonstrated in paper 1, studies on immune profiles in BALF from patients with DPLD and 
HC provide insights into the immune processes, and may possibly reveal clues to the 
immunopathology that can be modified by therapy.   
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4.3 CD4+ T CELL SUBSETS IN SARCOIDOSIS (PAPER 3) 
 
In sarcoidosis, IFN-γ+ CD4+ T cells and Th1-related cytokines IFN-γ, IL-2 and TNF-α are 
elevated in BALF, as well as the anti-inflammatory cytokine IL-10. Subgroups of patients 
with good prognosis tend to exhibit a less pronounced Th1-response [171]. 
  
BALF Regulatory T cells are decreased in sarcoidosis 
Regulatory T cells, characterized by expression of the transcription factor FoxP3, produce IL-
10, and are essential for immunoregulation at mucosal tissues such as the lungs[118]. We 
investigated expression of FoxP3 in BALF CD4+ T cells in patients with sarcoidosis (N=30), 
other DPLD (N=18) and HC (N=15), and found significantly lower fractions in sarcoidosis, 
compared to other DPLD or HC (median: 3.4% versus 7.1%, p=0.001 and versus 5.3%, 
p=0.017, figure 10a). These results are in agreement with two other studies, in Swedish [137] 
and Chinese patients[172], but at variance with a report from France [135]. In the latter report, 
regulatory T cells were defined as CD25bright CD4+ T cells, and FoxP3 expression was 
confirmed in the majority of these cells by a PCR-approach, making direct comparison less 
relevant. CD25 is the α-chain of the IL-2 receptor, and is also intermediately expressed by the 
majority of non-regulatory human memory CD4+ T cells [173].  
In sarcoidosis, peripheral blood lymphopenia and anergy to particular antigens such as 
tuberculin protein are common [174]. Lymphocyte depletion due to increased infiltration of 
lymphocytes in target organ may explain both phenomena, although anti-proliferative activity 
exerted by peripheral regulatory T cells has also been suggested to explain the state of anergy 
[135]. Similarly, FoxP3+ CD4+ T cells are reported to be augmented and the CD4/CD8-ratio 
lower in enlarged mediastinal lymph nodes compared to BALF. However, the immune 
process in sarcoidosis is believed to be primarily located to the airways and alveoli, possibly 
as a response to an inhaled antigen[125]. This is also consistent with the bronchovascular 
distribution of the lung noduli often seen on HRCT.   
Interestingly, regulatory T cell populations may contract due to IL-2 deficiency under specific 
inflammatory conditions[175], such as Toxoplasma gondii infection, where an excessive IFN-
γ-production leads to IL-2 shutdown. Similarly, both Th17-responses and IL-27, a cytokine 
thought to play a role in the initiation and resolution of a Th1-response, downregulate the 
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regulatory T cell pool via effects on IL-2[176]. It is conceivable that some of these 
mechanisms might contribute to the decreased fraction of BALF regulatory T cells observed 
in the current study. Figure 8 illustrates how the amount of IL-2 is a limiting factor controlling 
regulatory T cell homeostasis during infection.   
Recent studies have explored the phenotypes and function of subsets of FoxP3+ regulatory T 
cells in non-lymphoid tissues, and subsets specialized in regulating Th1, Th2 or Th17 
polarized immune responses have been found [177]. These studies serve as an interesting 
background for our study on regulatory T cell phenotypes in the lung/mucosal system of the 
respiratory tract, both in the context of regulatory T cells in non-lymphoid tissues and under 
inflammatory conditions (the profound Th1-polarized immune response of sarcoidosis). 
 
 
Figure 9: Disordered regulatory T cell homeostasis during infection 
In normal homeostasis a limited amount of IL-2 produced by non-regulatory CD4+ T cells controls the balance 
between proliferation and apoptosis in the population of regulatory T cells (a). During inflammation, the 
proliferation of conventional CD4+ T cells is accompanied by excess production of IL-2, allowing a balanced 
expansion, and subsequently contraction of the population of regulatory T cells (b). Under some conditions, 
deficiency of IL-2 may limit the population of regulatory T cells, allowing an unchecked expansion of 
conventional CD4+ or CD8+ T cells (c).  Reprinted by permission from Macmillan Publishers Ltd: Nature 
Reviews Immunology [175], copyright (2014). 
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We did not find any correlation between the frequency of FoxP3+ CD4+ T cells and 
radiological stage or Löfgren’s syndrome in our material. However, only five patients 
presented with Löfgren’s syndrome, and four patients had radiologic stage 3 or 4.     
 CD27, a tumor necrosis factor receptor 
superfamily member, plays a role in maintaining T 
cell survival, and is transiently expressed on T 
effector cells during activation. The majority of 
FoxP3+ CD4+ T cells in all groups expressed 
CD27 [median (IQR): 87 (79-95) %], confirming 
that CD27 may serve as a surface marker of 
regulatory T cells in BALF, as suggested by others 
[178]. The ectonucleotidase CD39 is highly 
expressed on regulatory T cells, and serves as an 
effector mechanism by hydrolysis of extracellular 
ATP, but is also expressed by non-regulatory T 
cells[179]. We found expression of CD39 on the 
majority of BALF FoxP3+ CD4+ T cells [median (IQR): 66 (44-80) %], but there was no 
significant difference between the patients and controls.  
 
Figure 11: Frequency of CD4+ T cell subsets in bronchoalveolar lavage fluid 
FoxP3+ CD4+ T cells, Th17 and IFN-γ+ Th17 cells in patients with sarcoidosis, other diffuse parenchymal lung 
disease (DPLD) and healthy controls (HC). 
 
Figure 10: CD39 expression on FoxP3+ 
CD4+ T cells 
A typical patient with sarcoidosis. Eighty-
one % of the FoxP3+ CD4+ T cells 
expressed the surface marker CD39. 
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Th1, Th17 and IFN-γ+ Th17 and cells in sarcoidosis 
In patients with sarcoidosis, other DPLD and in HC, the majority of BALF CD4+ T cells were 
Th1 cells (IFN-γ+) (median: 75.5 %, 62.1 % and 65.7 %, respectively), and although the 
median fraction of Th1 cells was higher in patients with sarcoidosis, this difference failed to 
reach statistical significance. More than 80 % of CD8+ T cells produced IFN-γ in all groups. 
When testing for production of the cytokine IL-17 (Th17 cells) after culture of the cells in 
medium with mitogen, we found markedly lower fraction of Th17 cells in patients with 
sarcoidosis compared to HC (2.5 versus 4.5 % of CD4+ BALF T cells, p=0.011). This is 
consistent with one study from Sweden, in which gene expression of IL-17A in sorted CD4+ 
BALF T cells was found to be lower in patients with sarcoidosis than in HC [180]. On the 
other hand, several previous studies have found increased frequencies of Th17 cells in BALF 
and peripheral blood in sarcoidosis [129, 134, 172, 181]. Methodological differences such as 
stimulation protocol, gating of IL-17+ from IL-17- cells and the ability to obtain clean gates on 
CD4+ T cells may explain some of the variance between the studies (autofluorescent AM 
polluting the lymphocyte- or the CD4+ T cell gate may influence the fractions of cells counted 
as IL-17+). Importantly, characteristics of the study population, including genetic background, 
could probably explain differing results. Accordingly, our results are in line with the study 
from Sweden, but at variance with the studies on Chinese and American patients. 
In patients with sarcoidosis the majority of Th17 cells also produced IFN-γ (median: 72.4% of 
Th17 cells), while in BALF from HC, only median: 32% of Th17 cells produced IFN-γ 
(p=0.0005). This is consistent with recent reports on Th17 cells in BALF [181, 182] and 
peripheral blood [134, 181] in patients with sarcoidosis. 
Since their discovery a decade ago, the notion of Th17 cells as a stable, pro-inflammatory T 
helper cell subset has been challenged. Lately, it has been increasingly appreciated that Th17 
cells are a heterogeneous population with both pro- and anti-inflammatory effector functions 
and remarkable plasticity [183, 184]. Cytokine production by human Th17 cells is extensively 
regulated in tissue microenvironment and by commensal microbiota[185]. Two major subsets 
of Th17 cells have been described, with different homing receptors, one of which has the 
ability to produce IFN-γ[183]. In one study, Th17 cells induced by Candida albicans also 
produced the Th1 cytokine IFN-γ, whereas Th17 cells induced by Staphylococcus aureus 
produced IL-10, and not IFN-γ[133]. Furthermore, in a study utilizing a mouse model system 
with fate mapping of Th17 cells, IL-17 expression was rapidly lost during inflammatory 
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immune responses in vivo, and a substantial proportion of these cells instead produced IFN-
γ[186]. Accordingly, a substantial number of human Th17 cells seem to acquire Th1-
associated features such as expression of T-bet and IFN-γ in inflamed tissues, eventually 
differentiating to a Th1-like effector progeny, via a Th17-Th1 ‘phenotypic drift’[183]. IL-12 
and IFN-γ induce the shift of Th17 cells into IFN-γ+ Th17 cells and subsequently IL17-IFN-γ+ 
Th1-like cells (non-classical Th1 cells) [187, 188].  
In the present study, IFN-γ+ fractions of 
Th17 cells were highly correlated with Th1 
cells in patients with sarcoidosis (N=23, 
rho=0.64, p=0.001), other DPLD (N=11, 
rho=0.7, p=0.02), healthy controls (N=15, 
rho=0.91, p<0.00001) and in patients and 
HC combined (N=49, rho=0.75, p<0.0001) 
(figure 11). In sarcoid granulomas, AM 
produce the Th1-driving cytokine IL-12 in 
an inflammatory feedback loop with IFN-γ 
from Th1 cells. In addition, AMs produce 
TNF-α and IL-1β. Hence, the observation 
that the majority of Th17 cells in the 
present study also produce IFN-γ is fully consistent with current knowledge on the plasticity 
of Th17 cells. Similarly, the correlation of IFN-γ+ fractions of Th17 cells and Th1 cells may 
be a reflection of the concentration of Th1-driving cytokines in the microenvironment of the 
Th17 cells. This effect is also seen in non-sarcoidosis patients and HC, and may not be 
specific to the immune response in sarcoidosis. Moreover, as we found a decreased frequency 
of Th17 cells in sarcoidosis, it is tempting to speculate that this could be a consequence of the 
‘phenotypic drift’ of Th17 cells into Th1-like cells. In addition, the rarity of Th17 cells at 
inflammatory sites may also be explained by their impaired IL-2 production in response to 
TCR signaling, limiting their expansion [189, 190]. 
The question remains, however: Are Th17, IFN-γ+ Th17 or Th1-like cells pathogenic? Th17 
cells have been associated with several human diseases with suspected autoimmune etiology, 
including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and psoriasis 
[106, 191, 192]. IFN-γ+ Th17 have been reported to be pathogenic in multiple sclerosis and 
Figure 12: The fraction of Th1 cells was highly correlated 
with fractions of Th17 cells producing IFN-γ. HC: Healthy 
control. DPLD: Diffuse parenchymal lung disease. 
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mice with experimental autoimmune encephalomyelitis [131, 132]. However, the emerging 
picture of Th17 cells and their pathogenic potential is complex, and depending on the 
different experimental model or the inflammatory disorder Th1, Th17, IFN-γ+ Th17 or Th1-
like cells may all be involved in tissue damage[189]. In the present study, fractions of IFN-γ+ 
Th17 cells increased with radiologic stage (rho=0.45, p=0.03). This may be a result of a more 
Th1-polarized cytokine milieu on Th17 cells, as reduced expression of Th1-cytokines has 
previously been reported in patient subgroups with particularly good prognosis[171]. Still, 
this does not preclude the possibility that IFN-γ+ Th17 cells or their progeny are pathogenic, 
and the contribution of these cells in the immunopathology of sarcoidosis is yet unresolved. 
An interesting observation in this respect is that TNF-α inhibitors, which have been used in 
sarcoidosis refractory to other treatments, may inhibit the transition of Th17 cells to IFN-γ+ 
Th17 or Th1-like cells, as Th17 cells express TNF-α receptor II [189]. 
The balance between CD4+ T cell subsets in sarcoidosis 
An increased ratio of Th17 to FoxP3+ CD4+ T cells has been reported in sarcoidosis[172]. 
This was not confirmed in our study, although the ratio of Th1/ FoxP3+ CD4+ T cells was 
higher in sarcoidosis compared to other DPLD and compared to HC [median (IQR): 21.7 
(14.4-35.2) versus 6.2 (2.8-13.5), p=0.002, and versus 9.5 (8.9-13-6), p=0.009]. Thus, the 
expansion of Th1 cells in sarcoidosis is not accompanied by a proportional expansion of 
FoxP3+ CD4+ T cells, possibly due to deficiency of IL-2 (see section on regulatory T cells). 
Similarly, the ratio of IFN-γ+ Th17 to FoxP3+ CD4+ T cells was considerably increased in 
sarcoidosis compared to other DPLD and compared to HC [median (IQR): 16.5 (8.9-48.3) 
versus 5.9 (2.8-11.1), p=0.005, and versus 4.9 (3.3-8.4), p=0.0004]. This ratio conveys the 
information that the combination of high fractions of INF-γ+ Th17 cells and low frequency of 
FoxP3+ CD4+ T cells is typical of sarcoidosis. Patients with other DPLD tend to have higher 
fractions of FoxP3+ CD4+ T cells. Accordingly, the balance of CD4+ T cell subsets is altered 
in sarcoidosis compared to other DPLD and HCs. 
We found no correlation between fractions of Th1, Th17 or FoxP3+ CD4+ T cells and either 
sarcoidosis stage according to Scadding, or Löfgren’s syndrome. However, the number of 
patients with Löfgren’s syndrome or stage 3 or 4 sarcoidosis according to Scadding’s 
classification is too low in the present study to exclude the possibility that such correlations 
exist.
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6 CONCLUSIONS 
 
Lymphocyte phenotypes NKT cells and HLADR+ CD8+ T cells are augmented in BALF from 
patients with HP. These markers provide a possible tool for discrimination of patients with HP 
from sarcoidosis. The presence of NKT cells in HP may provide clues to the immune 
response in HP. 
The use of BALF immune cell profiles and lymphocyte phenotypes may be used to predict the 
probability of sarcoidosis in the individual patients, yielding high diagnostic accuracy in our 
study population. The addition of lymphocyte phenotypes NKT cells and HLADR+ fractions 
of CD8+ T cells increases the diagnostic accuracy of BALF investigations in sarcoidosis. 
BALF Regulatory T cells and Th17 cells are both decreased in sarcoidosis. The majority of 
Th17 cells also produced IFN-γ, whereas only 1/3 of Th17 cells in HCs produced IFN-γ. This 
fraction was highly correlated with fractions of Th1 cells in all groups, indicating that a Th1-
polarized immune response induce IFN-γ in BALF Th17 cells, or alternatively a common 
factor induce both a Th1 response and IFN-γ in BALF Th17 cells. The fraction of Th17 cells 
producing IFN-γ is correlated with severity of sarcoidosis in terms of radiological stage. 
Furthermore, the expansion of Th1 cells in sarcoidosis was not accompanied by a comparable 
expansion of FoxP3+ CD4+ T cells. 
These studies provide evidence of altered cellular immune responses in sarcoidosis and HP 
that can be used as diagnostic markers, and may contribute to our knowledge of the 
immunopathology of the disorders. 
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7 FUTURE ASPECTS 
The use of BALF in a predictive, diagnostic model, discussed in paper 2, makes an inspiring 
base for future studies. In the future, we might be able to ‘fingerprint’ the immune profiles in 
sarcoidosis and HP, possibly eliminating the need for transbronchial or transthoracal biopsies. 
To achieve this, a more comprehensive profiling of immune cell phenotypes in a larger 
number of patients is needed.  
The study of complex cellular systems, such as T cell functional responses in pathological 
conditions, will be aided by the recent advancements in deep profiling techniques[193], such 
as polychromatic FC, and the feasibility of high dimensional, high throughput single cell 
analysis[194]. The recent increments in numbers of parameters measured in FC has 
introduced a need for analysis platforms that are able to handle the complexity of n-
dimensional datasets, as well as enable human-readable graphical visualizations of the 
data[193, 195]. An interesting example on this is the Bioconductor project 
(www.bioconductor.org) which provides open software for computational biology and 
bioinformatics in the R environment [196], including tools for gating and analysis of 
polychromatic FC and graphical visualization of complex data. Automated flow cytometry 
data analysis techniques have recently been reviewed [197]. 
In a future study the number of parameters analyzed in FC could be increased (or 
alternatively, mass cytometry could be used), to provide an in-depth phenotyping of both 
lymphocytes and AM in BALF from patients with sarcoidosis and other DPLD. An enhanced 
predictive model discriminating patients with sarcoidosis could then be developed, and the 
diagnostic accuracy tested prospectively, in a new cohort of patients. Parallel to this, an 
algorithm for automated flow cytometry data analysis could be generated and tested. We 
could provide a comparison of manual and automated gating of BALF cells. 
A future study on the NKT cells (or NKT-like cells) seen in BALF from patients with HP, and 
in some other diseases (paper 1 and 2) may be justified. This cell population could be sorted 
and cultured, and the phenotype, cytokine profile and functional characteristics could be 
explored.  
Similarly, deep profiling and functional studies of T cells subsets in the lung in sarcoidosis, 
utilizing FC with increasing number of colors, mass cytometry or single cell PCR may 
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provide insight into the nature and function of regulatory T cells and Th17 in sarcoidosis and 
quantify the Th17 derived Th1-like cell population.  
Ultimately, such studies may identify patterns that are linked to the development of fibrotic 
sarcoidosis, and possibly identify molecular targets for treatment. 
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Abbreviations:
BALF: Bronchoalveolar lavage fluid, DPLD: diffuse
parenchymal lung diseases, HP: hypersensitivity pneu-
monitis, HRCT: High Resolution Computed Tomography,
HLA: Human leucocyte antigen, NKT cell: Natural killer
T cell, TCR: T cell receptor, IQR: Inter quartile range.
Introduction
Sarcoidosis and hypersensitivity pneumonitis
(HP) are diffuse parenchymal lung diseases (DPLD)
characterized by formation of non-caseating granu-
lomas with a bronchocentric distribution. In HP, the
inflammation is an immune response to an inhaled
antigen in predisposed individuals (1), and over 300
antigens, predominantly organic in nature, have been
identified. In contrast, the inciting antigen in sar-
coidosis has not yet been identified(2), but an in-
haled antigen is suspected (3, 4).
Analysis of the white blood cell differential pro-
file in bronchoalveolar lavage fluid (BALF) can be a
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useful supplement in the diagnostic work-up of
DPLD (5). Although not diagnostic, relative and
absolute number of lymphocytes are increased in sar-
coidosis and HP (6). The lymphocytic alveolitis in
sarcoidosis is dominated by CD4+ T cells with an in-
creased CD4/CD8 ratio. In contrast, the alveolitis in
HP is often dominated by CD8+ T cells, resulting in
an inverted CD4/CD8-ratio, together with an in-
crease in relative numbers of mast cells, neutrophils
and foamy alveolar macrophages(7). However, con-
siderable overlaps are seen between the diseases, as
the CD4/CD8 ratio can also be increased in HP, and
different causes of HP may cause different BALF
cellular patterns (7, 8)
Lymphocyte subsets in the BALF may be iden-
tified and quantified by the use of monoclonal anti-
bodies and flow cytometry. In sarcoidosis and HP,
there is an increased expression of the activation
marker HLA-DR on T-lymphocytes in the BAL
fluid. HLA-DR expression is increased in CD4+ T
cells in both diseases (9, 10), and is lower in CD8+ T
cells in sarcoidosis than in HP (10, 11). Natural
Killer T (NKT) cells, a subset of T cells expressing
the NK cell markers CD56 and/or CD16, are in-
creased in HP(12). As far as we are aware, the com-
bined use of these subsets has not been reported pre-
viously in HP and we report our findings on these
two lymphocyte subsets in sarcoidosis, HP and
healthy controls.
Materials and methods
Study population
Between September 2007 and September 2012,
bronchoscopy and flow cytometric analysis of BALF
samples were performed in all patients investigated
for suspicion of DPLD in our institution. Of these
patients, 146 were given a clinical diagnosis of sar-
coidosis or HP, and were eligible for inclusion in the
study. Patients on systemic corticosteroid or other
immunosuppressive treatment or active cancer at the
time of bronchoalveolar lavage were excluded from
the study. In addition, patients who did not meet the
diagnostic criteria for sarcoidosis and HP were ex-
cluded. The final diagnoses of the included patients
were sarcoidosis (N=83) and HP (N=10) (figure 1).
Sixteen patients presented with Löfgren’s syndrome.
Healthy control subjects (N=15) with no known
history of asthma or allergy were recruited by adver-
tisement on the hospital web-site. All subjects had
normal CO diffusing capacity.The FEV1/FVC ratio
was below 0.7 in one subject (0.67), a second subject
had a FEV1 of 76% of predicted value and a third
subject was on anti-hypertensive therapy.
Demographics of the study population are pre-
sented in table 1.
The Regional Ethics Committee assessed that
use of patient data did not require ethical approval as
it was considered to be a quality control of a routine
clinical investigation (Ref.nr.: 2009/909-2). Ethical
approval (Ref.nr.: 2010/1939-4) and written in-
formed consent were obtained for bronchoscopy
with bronchoalveolar lavage in control subjects.
Diagnostic criteria
The diagnostic criteria of sarcoidosis were a
clinical and radiological pattern consistent with sar-
coidosis, presence of non-caseating granulomas on
biopsy, and exclusion of other known causes of gran-
ulomatous diseases(13). Histological demonstration
of granuloma was not required for patients with clas-
sic features of Löfgren’s syndrome, defined as fever,
erythema nodosum and/or ankle arthritis together
with bilateral hilar lymphadenopathy.
Patients with HP had at least 4 of the major cri-
teria and 2 of the minor criteria as suggested by
Schuyler et al. (14).The major criteria are: symptoms
Fig. 1. Study population.HP: Hypersensitivity pneumonitis
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compatible with HP, serologic evidence or a history
of antigen exposure, chest radiograph or High Res-
olution Computed Tomography (HRCT) findings
compatible with HP, lymphocytosis in the BALF,
compatible histologic findings on lung biopsy and
reproduction of symptoms after exposure to the anti-
genic environment. The minor criteria are: bibasilar
rales, decreased diffusing capacity and arterial hy-
poxemia.
BAL procedure and flow cytometry
Bronchoscopy with bronchoalveolar lavage was
performed in accordance with recommenda-
tions(15), as previously described(16). In brief,
lavage was done with 2-3 aliquots of 60 ml phos-
phate buffered saline (Hospital pharmacy, Hauke-
land University Hospital, Bergen, Norway) under
local anaesthesia with lignocaine and intravenous se-
dation with midazolam and alfentanyl. The first
fraction was used for microbiological or cytological
analyses, and the remainder of the lavage fluid was
pooled, filtered through nylon gauze and kept at 4°
C until processing.
The total cell count was made by ADVIA 120
Hematology System (Siemens AG, Erlangen, Ger-
many). Differential cell counts of a minimum of 300
cells were performed on cytospin preparations
stained with May Grünwald/Giemsa.
Cell pellets were prepared by centrifugation for
5 min at 1500 rpm. Tubes containing 0.5-1.0 x 106
cells per tube were incubated for 15 minutes with se-
lected antibodies as detailed in table 2. The cells
were then washed twice in 2 ml phosphate buffered
saline containing 0.1% bovine serum albumin (Dul-
becco A, Sigma-Aldrich, St. Louis, USA).
Flow cytometry of a minimum of 10.000 cells
was performed with a FACS Canto I flow cytometer
with FACS DIVA software (BD Biosciences,
Mountain view, CA,USA). Lymphocytes were iden-
tified as CD45+ cells with low side and forward scat-
ter. An isotype control tube was used to set the gates
to discriminate HLA-DR+ and HLA-DR- lympho-
cytes. NKT cells were defined as CD3+ lymphocytes
with expression of CD16/CD56, and the gates were
set by visual comparison to the dominating popula-
tion of CD16/CD56- T cells. In October 2010, the
tube for identification of NKT cells was changed in
our laboratory, and NKT cells in subsequent patients
(Sarcoidosis: N=30, HP: N=4, HC: N=15) were de-
fined as CD3+ lymphocytes with expression of
CD56 (CD16 was omitted from the antibody pan-
el). Gating strategy is presented in figure 2.
Statistical methods
Group comparison of continuous data was done
with Kruskal-Wallis test. Post hoc analyses were per-
formed with pairwise Wilcoxon rank sum test and
Table 2.Antibody panel
Tube Antibody conjugates
FITC PE PerCP-Cy5.5 APC
1 Isotype Isotype Isotype Isotype
control1 control1 control2 control1
2 CD81 CD41 HLA-DR2 CD31
3 CD33 CD163 and CD563 CD453 CD193
1 Multimix, Dako Denmark AS, Glostrup Denmark, 2 BD Bio-
sciences, San Jose, USA, 3MultiTEST™, BD Biosciences. FITC:
Fluorescein isothiocyanate, PE: phycoerythrobilin, PerCP-Cy5.5:
Peridinin chlorophyll protein with cyanine dye (Cy5.5), APC:
Allophycocyanin
Table 1. Demographics and BAL differential cell counts of study population
Sarcoidosis HP HC P
(N=83) (N=10) (N=15)
Age, years* 48 (18-77) 54 (39-72) 35 (21-53) 0.003
Sex (male/female) 61/22 6/4 8/7 0.22
Smoker/non-smoker 6/76 0/10 0/15 0.77
Total cell count (x 106/ml) 0.19 (0.14-0.29) 0.39 (0.25-0.53) 0.14 (0.12-0.17) 0.0009
Lymphocytes (%) 31 (21-52) 69 (66-74) 14 (10-25) <0.0001
Neutrophils (%) 2 (1-6) 5 (3-6) 4 (2-5) 0.35
Eosinophils (%) 0 (0-1) 4 (1-7) 0 (0-0) 0.0009
Alveolar macroph. (%) 57 (39-75) 21 (15-28) 81 (69-85) <0.0001
Fisher exact test was used for categorical variables and Kruskal-Wallis test for continuous variables. *Data shown as median (range). All oth-
er data are shown as median (IQR). HP: Hypersensitivity pneumonitis. HC: Healthy control subjects
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the Bonferroni correction for multiple comparisons.
Categorical data were analyzed with Fishers exact
test. A p value of < 0.05 was considered to be statis-
tically significant. Statistical analyses were done in
R: A Language and Environment for Statistical
computing (R Core Team, R Foundation for Statis-
tical Computing, Vienna, Austria).
Results
In HP, the BALF NKT cell fraction was over 7-
fold and 18 -fold greater, respectively, than in sar-
coidosis and controls [median (IQR): 5.5% (3.5-8.1)
versus 0.7% (0.5-1.2), p<0.0001, and versus 0.3%
(0.3-0.6), p=0.0001]. The HLA-DR+ fraction of
CD8+ lymphocytes were almost two- fold and 2.5-
fold greater, respectively, than in sarcoidosis and con-
trols [median (IQR): 79% (75-82) versus 43% (34-
52), p<0.0001, and versus 30% (26-34), p=0.0001].
HLA-DR CD4+ lymphocyte fraction was almost
one and a half- fold and two- fold greater, respec-
tively, than in sarcoidosis and controls [median
(IQR): 89% (81-93) versus 69% (60-79), p=0.0002,
and versus 45% (36-57), p=0.0001] (Figure 3).
Typical patterns of NKT cells and HLA-DR+
CD8+ cells in HP and sarcoidosis are shown in fig-
ure 4. The difference in HLA-DR expression on
CD4+ T cells in HP compared to sarcoidosis patients
was less striking in comparison to that on CD8+ cells
(figure 5b). The combination of high fractions of
NKT cells and HLA-DR+ CD8+ T cells was more
suggestive of HP than sarcoidosis (figure 5).
The NKT cell fraction and HLA-DR+ fraction
of CD8+ and CD4+ lymphocytes were higher in sar-
coidosis compared to controls (p=0.02, p=0.01 and p
< 0.0001).
As expected, the CD4/CD8- ratio was higher
in sarcoidosis compared to HP and healthy controls
(p=0.006 and p=0.010) (Fig. 3).
Fig. 2.Gating strategy.The example is a typical HP patient. a) Lymphocytes are gated by their low forward and side scatter signal. b) From
the lymphocytes, the T-cells, NKT cells and NK cells (CD3-CD16/56+) are gated by expression of CD3 and CD16/CD56. Numbers rep-
resent fractions of leucocytes (CD45+ BALF cells). c) T cells are gated as CD3+ lymphocytes. d) CD4+ and CD8+ T cells. e) In the iso-
type control tube, the gates for HLA-DR were set so that > 97.5% of the lymphocytes was assigned negative. f ) and g) HLA-DR-gates
from e) were used to discriminate HLA-DR+ CD4+ and CD8+ T cells. In October 2010, the tube for identification of NKT cells was
changed in our laboratory, and NKT cells in subsequent patients (Sarcoidosis: N=30, HP: N=4, HC: N=15) were defined as CD3+ lym-
phocytes with expression of CD56 (CD16 was omitted from the antibody panel).
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Differential cell counts in BALF are presented
in table 1. BALF lymphocyte fractions were more
than two-fold greater in patients with HP compared
to sarcoidosis (p=0.0001). Fractions of eosinophils
were higher in HP patients (p=0.008), and fractions
of alveolar macrophages were almost threefold
greater in patients with sarcoidosis compared to HP
(p<0.0001). There was a strong trend towards high-
er total cell count in HP compared to sarcoidosis, al-
though this was not significant after multiple com-
parisons correction (p=0.052).
Discussion
This study investigated the HLA-DR+ fractions
of CD8+ and CD4+ T cells and fractions of NKT
cells in BALF in patients with sarcoidosis, HP and
Fig. 3. Higher fractions of NKT cells and HLA-DR+ CD4+ and HLA-DR+ CD8+ T cells in hypersensitivity pneumonitis than in sar-
coidosis and healthy controls. a) HLA-DR expression on CD4+ was higher in sarcoidosis than healthy control subjects, while HP patients
had highest expression of HLA-DR on CD4+ T cells of all groups. b) HLA-DR+ fractions of CD8+ T cells, and c) fraction of NKT cells
were highly significant raised in HP versus sarcoidosis and HC, and significantly higher in sarcoidosis compared to healthy control sub-
jects. d) HP patients have lower CD4/CD8-ratio than patients with sarcoidosis. Kruskal-Wallis with post hoc multiple comparison and p-
value adjustment with Bonferroni correction. HP: Hypersensitivity pneumonitis; HC: Healthy control subjects.
321BALF lymphocyte subsets in HP and sarcoidosis
healthy control subjects. In addition to a decrease in
the CD4/CD8 ratio and an increase in lymphocytes
and eosinophils, HLA-DR CD8+ and NKT lym-
phocyte subsets were augmented in HP compared to
sarcoidosis patients. To our knowledge, these subsets
have not previously been investigated simultaneous-
ly. Together, fractions of HLA-DR+ CD8+ T cells
and NKT cells in BALF seem to discriminate very
well between HP and sarcoidosis, suggesting that
these markers may be a valuable tool in the diagno-
sis of HP and sarcoidosis. Fractions of HLA-DR+
CD4+ T cells, on the other hand, may be less useful
in discriminating HP from sarcoidosis.
The combined use of NKT cells and HLA-DR
expression on CD8+ T cells in the BALF as a diag-
nostic tool in HP has not been addressed in prior
Fig. 4. Flow cytometry scatter plots and histograms inHypersensitivity pneumonitis and Sarcoidosis.Scatterplot of NKT cells and his-
tograms displaying HLA-DR+ CD4+ and CD8+ lymphocytes for a) a typical hypersensitivity pneumonitis patient, and b) a typical sar-
coidosis patient. NKT cells are displayed in fraction of leucocytes. HLA-DR+ CD4+ and CD8+ T cells are fractions of CD4+ and CD8+ T
cells, respectively.
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studies. We previously reported that the use of these
markers improve diagnostic accuracy in sarcoido-
sis(16). A greater fraction of NKT cells in HP than
in sarcoidosis has been previously reported in a study
by Korosec et al. (12) who like us defined NKT cells
as CD3+CD16/56+ lymphocytes. In that study, NKT
cells are reported as a proportion of lymphocytes,
while we found it more suitable to report NKT cells
as a fraction of leucocytes. In patients with low lym-
phocyte fractions, noise in the flow cytometry gates
has a greater influence on the NKT cell fractions, if
reported as fractions of the lymphocytes. When re-
calculated as fractions of lymphocytes, we found a
median of 2.0% NKT cells in patients with sar-
coidosis and 7.6% in patients with HP (p=0.0004),
while they reported a median fraction of NKT cells
of 3% and 11% in sarcoidosis and HP.
Higher fractions of HLA-DR+ CD8+ T cells in
HP compared to sarcoidosis, has been reported in
one study(11). The difference in HLADR+ fractions
of CD8+ T cells in HP compared to sarcoidosis re-
ported by Heron et al. was less pronounced (median
96% versus 80%), although the principle findings
were similar. Interestingly, they reported a higher
fraction of HLA-DR+ CD8+ T cells in patients with
sarcoidosis and parenchymal involvement (radiolog-
ic stage II and higher) versus patients without
parenchymal involvement (median: 93% versus
77%), while this was not found in our study (medi-
an: 47% versus 42%, p=0.20). Dissimilarities in the
patient selection, anti-HLA-DR antibodies and
flow cytometry set-up may account for the varia-
tions.
Our study has limitations. Firstly, the number of
patients with suspected HP is small in our clinic, and
only 10 patients did fulfill the diagnostic criteria for
HP.The frequent inability to make a certain diagno-
sis of a specific DPLD, may lead to a tendency that
only the typical patients with HP are correctly diag-
nosed, while less typical patients more often are clas-
sified as unspecified DPLD. Secondly, our data are
insufficient to estimate the diagnostic accuracy of
NKT cell and HLA-DR+CD8+ lymphocyte fractions
as a test to discriminate HP from sarcoidosis. This
would have required a greater number of patients
with HP. However, a visual display of these two
markers in combination, as shown in figure 5a, sug-
gests that they may discriminate patients with HP
from sarcoidosis. Finally, due to a change in the an-
tibody panel in October 2010, NKT cells were de-
Fig. 5. Fractions ofHLA-DR+ CD8+T cells andNKT cells discriminate patients with hypersensitivity pneumonitis from patients with
sarcoidosis. Scatterplot of a) HLADR+CD8+ lymphocytes, and b) HLADR+CD4+ lymphocytes versus NKT cell fraction grouped for pa-
tients with hypersensitivity pneumonitis (HP) or sarcoidosis.
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fined as T cells expressing CD56 rather than
CD16/CD56 in a subset of the patients. This may
have resulted in lower fractions of NKT cells in these
patients and healthy control subjects. However, we
found no significant difference between NKT cell
fractions in sarcoidosis or HP patients investigated
with the former versus the newer antibody panel
(p=0.60 and p=0.48), whereas the NKT cell fractions
were significantly different in HP compared to sar-
coidosis also in the subgroup of patients analyzed
with the former antibody panel and in sarcoidosis
compared to healthy controls analyzed with the
newer antibody panel (data not shown). These re-
sults show that the change of antibody panel has not
influenced our principle findings. In addition, Ko-
rosec et al. reported that NKT cells in patients with
HP are mainly CD56+ (12), and thus would stain as
positive also with the newer antibody panel.
NKT cells are a heterogeneous population of
cells with elements of both the innate and the adap-
tive immune system, capable of rapid responses to
antigens with cytotoxic NK cell activity and produc-
tion of Th1 or Th2 cytokines. They are classified ac-
cording to their TCR, which can be invariant
(CD1d-restricted invariant NKT cells) or have nor-
mal variability in antigen specificity. CD8+CD56+ T
cells with an αβ TCR have been implicated in anti-
tumor immunity(17).The contribution of the various
NKT cell subsets and activated T cells to the patho-
genesis of either sarcoidosis or HP is not yet eluci-
dated. In HP, most of the NKT cells in BALF have
αβ TCR(12), and are CD8+CD56+, capable of both
antigen specific and NK-like cytolytic activities(18).
On the other hand, deficiencies and impaired INF-γ
production of CD1d restricted invariant NKT cells
in blood and BALF have been reported in sarcoido-
sis(19, 20). In this study, the NKT cells are defined as
CD16/CD56+ CD3+ lymphocytes. These cells are
strikingly increased in patients with HP compared to
sarcoidosis and HC, indicating a role of these cells in
the immunopathology of HP.
HLA-DR expression on T cells is a well known
activation marker, and may play a role in regulating
or limiting a specific T cell response to an anti-
gen(21). The fraction of HLA-DR+ CD8+ lympho-
cytes increases in some autoimmune diseases, as well
as with ageing, possibly as a part of normal im-
munoregulation(22), although its exact role is un-
clear. Activated CD4+ T cells of Th1 type produce
INF-γ, and is essential for the formation of granulo-
mas in sarcoidosis(23). The finding of increased ex-
pression of HLA-DR on CD4+ lymphocytes in sar-
coidosis may reflect the prominent role of activated
Th1 cells. In contrast, the HLA-DR+ CD8+ T cells
may be involved in the immunology of HP. It may
seem surprising that cytolytic T cells exhibit strong
activation in HP. The most important biological
function of cytolytic T cells is to kill infected cells
and cancer cells. Infection is not a central element in
HP even though many kinds of fungi and bacteria
have been identified as important sensitizing envi-
ronmental agents. Contrary to this, helper T cells are
central both in activating allergen-clearing
macrophages and in the production of allergen-spe-
cific antibodies, which are among the important
characteristics of the disease.
Identifying exposure to an antigen known to
cause HP is often difficult, and surgical lung biopsy
may be necessary to confirm the diagnosis. Howev-
er, surgical lung biopsy may not be achievable in all
patients, due to procedure related risks, patient pref-
erences or the severity of the disease. Therefore, our
demonstration of a BALF lymphocyte subset pat-
tern that may discriminate HP from sarcoidosis may
be relevant and helpful in this clinical situation. In
addition, the considerable overlap in CD4/CD8 ra-
tio seen in patients with HP and sarcoidosis in the
present study emphasize the need for more accurate
diagnostic markers.
In conclusion, our study suggests a role for the
combined use of NKT cell and HLA-DR+CD8+ T
cell fractions in BALF as diagnostic markers in HP
and sarcoidosis. However, further studies with a
greater number of patients with HP are necessary to
evaluate the diagnostic accuracy of these lymphocyte
subsets. In addition, functional studies on NKT cells
and HLA-DR+CD8+ T cells in BALF may provide
important clues to our understanding of the im-
munopathogenesis of both diseases.
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Abstract
Purpose The clinical diagnosis of pulmonary sarcoidosis
is based on the presence of noncaseating granulomas in an
appropriate clinical setting with either bilateral hilar ade-
nopathy and/or parenchymal inﬁltrates. Lymphocytosis
with an increased CD4/CD8 T cell ratio in bronchoalveolar
lavage ﬂuid is supportive. We evaluated the diagnostic
accuracy of a predictive binary logistic regression model in
sarcoidosis based on sex, age, and bronchoalveolar lavage
ﬂuid cell proﬁle with and without the inclusion of HLA-
DR? CD8? T cells and natural killer T-cell fractions.
Methods A retrospective analysis of differential cell
counts and lymphocyte phenotypes by ﬂow cytometry in
bronchoalveolar lavage was performed in 183 patients
investigated for possible diffuse parenchymal lung disease.
A logistic regression model with age, sex, lymphocyte
fraction, eosinophils, and CD4/CD8 ratio in bronchoalve-
olar lavage ﬂuid (basic model) was compared with a ﬁnal
model, which also included fractions of HLA-DR? CD8?
T cells and natural killer T cells. Diagnostic accuracy of the
two models was assessed by receiver operating character-
istic (ROC) curves.
Results The area under the ROC curve for the basic and
ﬁnal model was 0.898 [95 % conﬁdence interval (CI)
0.852–0.945] and 0.937 (95 % CI 0.902–0.972), respec-
tively, p = 0.008.
Conclusions Assessment of HLA-DR? CD8? T cell and
natural killer T-cell fractions may improve diagnostic
accuracy and further strengthen the importance of bron-
choalveolar lavage in the diagnostic workup of sarcoidosis.
Keywords Sarcoidosis  Lymphocyte subsets 
Bronchoalveolar lavage ﬂuid  Predicitive model 
Logistic regression  NKT cells  HLA-DR
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Introduction
Sarcoidosis is a multisystem inﬂammatory disorder of
unknown aetiology. The lung is the most commonly
affected organ, with heterogeneous involvement of the
bronchovascular and subpleural parenchyma and intratho-
racic lymph nodes. The diagnosis of pulmonary sarcoidosis
is based on the ﬁnding of noncaseating granulomas in
either bronchial or transbronchial biopsies or transbron-
chial needle aspirates of enlarged lymph nodes, in an
appropriate clinical setting and in the absence of other
known causes of granulomatous disease.
Analysis of bronchoalveolar lavage ﬂuid (BALF) for
total and differential counts of inﬂammatory cells and the
CD4/CD8 ratio has been considered a useful supplement in
the diagnostic workup of selected diffuse parenchymal
lung diseases (DPLD) [1], such as sarcoidosis [2], hyper-
sensitivity pneumonitis (HP) [3, 4], and eosinophilic
pneumonia [5]. In sarcoidosis, the characteristic ﬁndings in
BALF are a T-cell–dominated lymphocytosis and a CD4/
CD8 ratio[3.5 [6]. However, the latter can be inverted [7]
and in elderly subjects also normally increased [8]. The
CD4? T cells express the human leucocyte antigen acti-
vation marker (HLA-DR) [2]. However, HLA-DR expres-
sion on CD8? lymphocytes is lower in sarcoidosis than in
HP [9], suggesting that this may be useful in differentiating
sarcoidosis from other DPLD. Another lymphocyte subset
of interest is the natural killer T (NKT) cells, which express
CD56 and/or CD16, as well as the T-cell receptor (TCR).
The proportion of NKT cells in BALF has been found to be
lower in sarcoidosis than in HP [10].
The purpose of this retrospective study was to evaluate
the diagnostic accuracy of BALF in sarcoidosis in a pop-
ulation of suspected DPLD after initial clinical evaluation,
using a logistic regression model with and without HLA-
DR? CD8? lymphocytes and NKT cells in order to eval-
uate whether the inclusion of these two lymphocyte subsets
increases diagnostic accuracy.
Materials and Methods
Study Population
All patients investigated with bronchoscopy and ﬂow
cytometric analysis of BALF samples between September
2007 and June 2010 were considered eligible for inclusion
in the study if a DPLD was a possible differential diagnosis
after initial clinical evaluation and high-resolution com-
puted tomography (HRCT) thorax and not receiving
treatment with systemic corticosteroids at the time of
lavage. Patients with missing data or technical error in ﬂow
cytometry were excluded. The remaining patients were
then grouped on the basis of the diagnosis reached by the
attending respiratory physician after investigative workup
into sarcoidosis (N = 76) and nonsarcoidosis (N = 132).
For the purpose of this study, 51 patients fulﬁlled the fol-
lowing diagnostic criteria for sarcoidosis: a clinical and
radiological pattern consistent with sarcoidosis, presence of
noncaseating granulomas on endobronchial (4 patients) or
transbronchial (38 patients) biopsy or endobronchial
ultrasound-guided ﬁne needle aspiration (4 patients) of
mediastinal or hilar nodes, and exclusion of other known
causes of granulomatous disease [6]. In one patient, gran-
ulomas were found only in extrapulmonary tissue (liver
biopsy and bone marrow). The presence of granulomas was
not required in 11 of these patients with Lo¨fgren’s syn-
drome, deﬁned as fever, erythema nodosum, and/or ankle
arthritis together with bilateral hilar lymphadenopathy.
Patients were stratiﬁed by ﬁndings on chest radiograph at
presentation into stages 0–4, according to Scadding [11].
21 patients who did not fulﬁll these criteria and four
additional patients with sarcoidosis and active cancer were
excluded (Fig. 1).
The regional ethics committee (REC Central, Norway)
did not consider the study to require ethical approval,
because it was regarded to be a routine clinical quality
control investigation and in accordance with the amended
Declaration of Helsinki (Ref. no.: 2009/909-2).
BAL Procedure
Fiberoptic bronchoscopy was performed in accordance
with established recommendations [12]. The bronchoscope
was wedged in a segmental bronchus with radiological
evidence of parenchymal changes or in the medial seg-
mental bronchus of the right middle lobe. See supple-
mentary material 1 for details on BAL procedure and total
and differential leucocyte count.
Flow Cytometry
The samples were analysed using a FACS Canto I ﬂow
cytometer, with FACS DIVA software (BD Biosciences,
Mountain View, CA), with a panel of antibodies in a four-
colour setup, as listed in Table 1. Data from a minimum of
10,000 cells were recorded for each tube. Standardized
gating was performed without any clinical information
about the individual patients. Gating strategy is displayed
in Fig. 2.
Statistical Methods
Binary logistic regression was used to estimate a func-
tion for the likelihood ratio (LR) of sarcoidosis. LR is
the probability of seeing a certain data set in a patient
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with a given disease divided by the probability of seeing
the same data set in a patient without the disease
[13]. Knowing LR, the posttest probability of sarcoidosis
can be calculated as:ðLR pretest probabilityÞ=ðLR 
pretest probability þ 1 pretest probabilityÞ. The pretest
probability was deﬁned as the prevalence of sarcoidosis in
the study population (51/183).
The prediction model was generated using age, sex, total
cell concentration, eosinophils, and neutrophils in differ-
ential counts, proportion of lymphocytes [14], and CD4/
CD8-ratio from ﬂow cytometry in BALF as variables. The
selection of variables was based on expected clinical rel-
evance [2, 5, 15]. Fractional polynomials, a tool in logistic
regression modeling, was used to ﬁnd the simplest
nonlinear transformation (if any) of continuous variables
[16]. Model ﬁt was increased signiﬁcantly by transforma-
tion of the variables age and proportion of lymphocytes.
Variables were then eliminated with backwards stepwise
elimination based on the Akaike information criterion [16].
Model ﬁt was not signiﬁcantly decreased by elimination of
neutrophils and total cell concentration, resulting in the
basic prediction model. The ﬁnal prediction model was
generated using the variables in the basic prediction model,
as well as HLA-DR? CD8? T cells and fraction of NKT
cell.
The LR and estimated posttest probability of sarcoidosis
for each individual patient was calculated from the basic
and ﬁnal prediction models. The diagnostic accuracy of the
basic and ﬁnal models was estimated as the area under the
receiver operating characteristic (ROC) curve [17, 18]. As
estimation of the model coefﬁcients and calculation of the
area under the ROC curve in the same cohort of patients
may give an overtly optimistic estimate of the diagnostic
accuracy [19], and as we lacked a new cohort for model
validation, we randomly selected data from half of the
patients for estimation of the model coefﬁcients, and tested
the diagnostic accuracy of the resulting model in the other
half [20, 21].This procedure was repeated 1,000 times in
both prediction models. The median value of the area under
the ROC curve with 95 % conﬁdence interval was calcu-
lated for each model.
Mann–Whitney U was used for group comparison of
continuous variables. Categorical data were analyzed with
Pearson chi squared test and differences between the
Eligible patients (N = 226) 
Sarcoidosis (N = 51)
Radiological stage * N
0 5
1 15
2 19
3 8
4 4
Non- Sarcoidosis (N = 132)
Hypersensitivity pneumonitis (N=9) 
Other DPLD (N=44)
IPF 7 
COP 4 
CT-DPLD 4 
Med.ass DPLD 2 
NSIP 3 
Others 7 
Unclassified 17
Wegeners granulomatosis (N=3) 
Infectious diseases (N=19) 
Cancer /Metastasis from (N=14)
Lymphoma 5 
Mammae 3 
Prostate 2 
BAC 2 
Colon 1 
Renal cell car. 1 
Other diagnoses (N=17) 
Postinfectious 8
Various 9
No diagnosis (N=26)
Excluded (N = 25)
Uncertain diagnosis (N=21)
Sarcoidosis with active cancer (N=4)
Clinical diagnosis of Sarcoidosis 
(N = 76) 
Excluded (N = 18)
Missing data (N=12)
Technical errors in FC (N=4) 
Fig. 1 Flowchart of included
and excluded patients.
Overview of the patients
included and excluded in the
study. FC ﬂow cytometry;
DPLD diffuse parenchymal
lung disease; IPF idiopathic
lung ﬁbrosis; COP cryptogenic
organizing pneumonia; CT-
DPLD connective-tissue
disease-associated DPLD;
Med.ass DPLD medication
associated DPLD; NSIP
nonspeciﬁc interstitial
pneumonia; BAC
bronchoalveolar carcinoma;
Renal cell car. renal cell
carcinoma. Asterisk indicates
radiological stage according to
Scadding [11]
Table 1 Flow cytometry antibody panel
Tube Antibody conjugates
FITC PE PerCP-Cy5.5 APC
1 Isotype
controla
Isotype
controla
Isotype
controlb
Isotype
controla
2 CD8a CD4a HLA-DRb CD3a
3 CD3c CD16c and
CD56c
CD45c CD19c
FITC ﬂuorescein isothiocyanate; PE phycoerythrobilin; PerCP-Cy5.5
peridinin chlorophyll protein with cyanine dye (Cy5.5); APC
allophycocyanin
a Multimix, Dako Denmark AS Glostrup Denmark
b BD Biosciences, San Jose, CA, USA
c MultiTESTTM, BD Biosciences
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logistic regression models with the likelihood-ratio test.
The area under the ROC curves was compared with the
method described by DeLong et al. [22]. R version 2.15.2
[R Core Team (2012) R: A language and environment for
statistical computing. R Foundation for Statistical Com-
puting, Vienna, Austria] was used for statistical analyses.
p value\0.05 was considered to be statistically signiﬁcant.
Results
BALF Cellular Proﬁles
The basic characteristics of the study population and data
on differential cell counts and lymphocyte immunopheno-
typing are presented in Table 2. Lymphocyte fraction and
CD4/CD8-ratio were almost threefold and 2.5-fold greater
in sarcoidosis than in nonsarcoidosis patients. Neutrophils,
eosinophils, and fraction of HLA-DR? CD8? lymphocytes
were signiﬁcantly lower, and the fraction of NKT cells was
signiﬁcantly higher in sarcoidosis patients.
In the subgroup of 44 sarcoidosis and 60 nonsarcoidosis
patients with BALF lymphocyte fraction above 15 %, the
median (IQR) NKT cell fraction was lower in sarcoidosis
than in non-sarcoidosis patients [0.31 (0.20–0.61) vs. 0.73
(0.25–2.14), p = 0.004]. Sarcoidosis patients were char-
acterized by the combination of high lymphocyte fraction,
a relatively low NKT cell fraction and a low fraction of
CD8? T cells expressing HLA-DR (Fig. 3).
HLADR? fractions of CD8? T cells and fractions of
NKT cells were not signiﬁcantly different in sarcoidosis
stages according to Scadding’s classiﬁcation
(HLADR?CD8? T-cell fraction: p = 0.45; NKT cell
fraction: p = 0.82; Kruskal–Wallis test).
Fig. 2 Gating strategy. a Lymphocytes were gated by their scatter
signal. b T cells and NKT cells were gated by their expression of CD3
(CD3 is part of the TCR complex) and CD16/CD56. Lymphocytes
were conﬁrmed to be CD45 positive and NKT cells were calculated as
proportion of leucocytes (all CD45-positive cells, not shown).
c Isotype control gating of lymphocytes. d and e HLA-DR? fractions
of lymphocytes for CD4? and CD8? T cells, respectively. The case
displayed is a patient with sarcoidosis
Lung
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Logistic Regression Models
Covariates and coefﬁcients for the basic and ﬁnal logistic
regression models are presented in Table 3.
The LR function for the ﬁnal model is:
LR ¼ exp ð14:919þ ð0:011 lymphocytesÞ  ð1:298
 ðlymphocytes=10Þ ð2ÞÞ þ ð0:060 CD4=CD8Þ
 ð0:126 eosinophilsÞ  ð0:174 ageÞ  ð0:589
 ðAge=100Þ ð2ÞÞ þ ð0:806 sexÞ  ð0:049
 HLADRþ CD8þ T cellsÞ  ð1:035
 NKT cell fractionÞ
A scatterplot of the predicted probabilities for sarcoidosis
using the ﬁnal model for the individual patients grouped
according to their diagnoses is displayed in Fig. 4.
ROC Curves
ROC curves based on the basic and ﬁnal regression models
are presented in Fig. 5. The area under the curve (95 % CI)
for the ﬁnal model was 0.937 (0.902–0.973) and the basic
model was 0.898 (0.851–0.945), p = 0.008. The median
area under the curves (95 %CI for themedian) after repeated
random subsampling were 0.898 (0.896–0.9) versus 0.866
(0.863–0.868) in the ﬁnal and basic models, respectively.
Discussion
In this study, we evaluated the diagnostic accuracy of two
predictive regression models in sarcoidosis diagnosis, with
Table 2 Characteristics of the
study population
* Data presented as median
(range). BALF data presented as
median (IQR). Numbers
represent fractions of
leucocytes, unless otherwise
stated
Characteristic Sarcoidosis
(N = 51)
Nonsarcoidosis
(N = 132)
p
Age (year)* 48 (27–77) 63 (7–85) \0.0001
Sex (male/female) 36/15 70/62 0.044
Smoker/nonsmoker 5/46 27/103 0.088
Differential cell count
Total cell count (x106/ml) 0.19 (0.13–0.29) 0.26 (0.16–0.47) 0.002
Lymphocytes (%) 29 (17–51) 12 (5–41) \0.0001
Neutrophils (%) 3 (1–10) 7 (2–32) 0.001
Eosinophils (%) 0 (0–1) 1 (0–4) 0.015
Alveolar macrophages (%) 54(39–75) 57(26–79) 0.559
Flow cytometry
Lymphocytes (%) 37.9 (20.5–57.0) 13.6 (5.5–46.9) \0.0001
T cells (% of lymphocytes) 88.4 (79.6–95.1) 81.9 (67.8–89.6) 0.0001
CD4/CD8 ratio 3.8 (2.1–8.9) 1.5 (0.7–2.8) \0.0001
NKT cells (%) 0.27 (0.12–0.56) 0.10 (0.01–0.62) 0.007
HLA-DR? CD4? T cells
(% of CD4? T cells)
65.6 (59.1–77.1) 71.7 (54.0–83.3) 0.238
HLA-DR? CD8? T cells
(% of CD8? T cells)
37.1 (27.6–48.8) 50.0 (33.3–71.6) 0.0003
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Fig. 3 NKT cells and HLA-
DR?CD8? T cells in
sarcoidosis, Løfgren’s
syndrome, and nonsarcoidosis.
Scatterplot of lymphocyte
fraction versus NKT cells
(a) and HLA-DR? fraction of
CD8? T cells (b). NKT cell
natural killer T cell
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lymphocytes, eosinophils, and CD4/CD8-ratio in BALF,
age, sex, the activation marker HLA-DR on CD8? lym-
phocytes and the fraction of NKT cells in BALF as
covariates. The diagnostic accuracy of the basic predictive
model with eosinophils and CD4/CD8 in BALF, age, and
sex is improved by the addition of HLA-DR on CD8?
lymphocytes and the fraction of NKT cells to the model.
These ﬁndings may be useful in cases where histologic
conﬁrmation cannot be obtained.
The ﬁnal model’s area under the ROC curve after cross-
validation of 0.898 indicates that these diagnostic markers
may be of value in the diagnostic workup of sarcoidosis.
Our ﬁndings suggest that there is role for lymphocyte
subset analyses in sarcoidosis diagnostics, which is in
contrast to recent recommendations [23]. Although mar-
ginally higher in sarcoidosis patients compared with non-
sarcoidosis patients, BALF NKT cell fractions are lower in
sarcoidosis than in nonsarcoidosis patients with lympho-
cyte fractions in BALF in excess of 15 %. From a clinical
point of view, the combination of elevated lymphocyte
fraction and relatively low fractions of NKT cell and
HLADR? CD8? T cell seem to discriminate patients with
sarcoidosis fairly well from other DPLDs. In contrast, the
combination of elevated lymphocyte fraction and high
fraction of NKT cells may be more suggestive of another
DPLD, such as HP than of sarcoidosis. In our population,
only 4 of 51 patients with sarcoidosis had an NKT cell
fraction[1 % of the BALF leucocytes. Similarly, only one
sarcoidosis patient had HLADR? CD8? T-cell fraction
[66 %. If the NKT cell or HLADR? CD8? T-cell fraction
is higher than that usually seen in sarcoidosis, the clinician
should be alert to the possibility for other diagnoses than
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ed
 p
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Non−sarcoidosis
Sarcoidosis
Löfgren’s
Fig. 4 Ability of the ﬁnal logistic regression model to predict
sarcoidosis. The ﬁnal model’s ability to predict sarcoidosis displayed
as a scatterplot of predicted probabilities (the calculated probability of
sarcoidosis for the 183 individual patients). The sensitivity and
speciﬁcity of the test will vary depending on the cutoff value for a
positive test. Grey circle represent predictions for patients with
Lo¨fgren’s syndrome. The dashed line on 25 % predicted probability
yields a sensitivity (true positives/sarcoidosis patients) of
47/51 = 0.922 and a speciﬁcity (true negatives/nonsarcoidosis
patients) of 105/132 = 0.795
Table 3 Logistic regression models
Covariate Basic model Final model
Coefﬁcient p value Coefﬁcient p value
Lymphocytes (%) -0.031 0.021 0.011 0.551
(Lymphocytes/
10)-2
-1.338 0.017 -1.298 0.021
CD4/CD8-ratio 0.131 0.018 0.060 0.32
Eosinophils -0.19 0.019 -0.126 0.15
Age -0.15 \0.0001 -0.174 \0.0001
(Age/100)-2 -0.47 0.003 -0.589 0.003
Sex (male) 1.017 0.027 0.806 0.11
NKT cells (%) -1.035 0.028
HLA-DR? CD8?
(%)
-0.049 0.002
Constant (adjusted)a 11.511 0.0001 14.919 \0.0001
Likelihood-ratio test (basic vs. ﬁnal): p\ 0.0001. Overview of the
coefﬁcients in the basic and ﬁnal model
a The Constant is adjusted for prevalence of disease [13] by the
formula Constant (adjusted) = Constant ? log (number of nonsar-
coidosis patients/number of sarcoidosis patients)
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Fig. 5 ROC curves for basic and ﬁnal prediction model. The area
under the curve for the black curve is a measure of the diagnostic
accuracy of the basic model in discriminating sarcoidosis from
nonsarcoidosis patients. The area under the curve increases by adding
NKT cells and HLA-DR?CD8? lymphocytes fractions as variables in
the model, as represented by the grey line (ﬁnal model). ROC receiver
operating characteristic; AUC area under curve
Lung
123
Author's personal copy
sarcoidosis. The prediction model can be developed easily
to clinical application for an individual patient, by calcu-
lating LR and posttest probability of sarcoidosis from the
formula speciﬁed in the methods section.
Logistic regression has been used previously in evalua-
tion of BALF proﬁles in diagnosis of sarcoidosis and other
DPLDs [15, 24–26] or sputum-negative tuberculosis [27]. A
computer program based on logistic regression in a predic-
tive model has been developed by Drent et al. [24] as a
diagnostic tool to discriminate the most common DPLDs.
Our study differed from those studies in two respects. First,
the regression model in the studies by Drent et al. [24] was
initially restricted to a selection of patients with sarcoidosis,
HP, or idiopathic pulmonary ﬁbrosis and was later extended
to include infectious disorders [26]. In our study, we inclu-
ded all patients where sarcoidosis or another DPLD was
considered as a differential diagnosis. This may be closer to
the clinical situation, where sarcoidosis may be considered
as a differential diagnosis in many patients with diffuse
interstitial inﬁltrates on HRCT. Second, the variables
selected in the models are different between the studies. Our
study also included lymphocyte subsets, which signiﬁcantly
increasedmodel ﬁt in our data.Many previous BALF studies
were conducted before the implementation of HRCT as a
routine investigation [23] in suspected DPLD and may be
difﬁcult to translate to the current clinical situation.
In the present study, we compared the expression of
HLA-DR on BALF CD8? T cells and fraction of NKT
cells in sarcoidosis and nonsarcoidosis patients. These
T-cell subsets have been investigated in two other studies
of DPLDs [9, 10]. In those studies, comparisons were made
between patients with sarcoidosis and HP, with a lower
fraction of BALF HLA-DR? CD8? lymphocytes [9] and a
lower fraction of NKT cells [10] in sarcoidosis. Our results
for HLA-DR? CD8? lymphocytes and for NKT cells in
sarcoidosis and nonsarcoidosis patients with lymphocyte
fractions in excess of 15 % are consistent with those
studies. However, to our knowledge the utility of both
markers in the diagnosis of sarcoidosis has not been eval-
uated in previous studies.
Our study has several limitations. One such limitation is
related to the frequent inability to make a deﬁnite diagnosis
of a DPLD. There were 21 patients with a clinical diagnosis
of sarcoidosis in the patient record, which were excluded
from the study because they did not fulﬁll the diagnostic
criteria. Of these patients, 10 had probable sarcoidosis with
typical clinical and radiological ﬁndings but no veriﬁed
granulomas on tissue samples, and 11 had either atypical
clinical course of the disease or atypical radiological pre-
sentation. Three patients in the latter group also had a
diagnosis of Crohn’s disease, and one patient had terminal
renal failure. Applying the ﬁnal model, the median (range)
predicted probability of sarcoidosis was: 75.6 % (1.9–95.8)
in the former group and 25 % (0.1–87.3) in the latter group.
Using a cutoff of 25 % predicted probability, as suggested
by the ROC curves, would support a diagnosis of sarcoidosis
in 9 of 10 in the former group and 5 of 11 patients in the latter
group. As these patients have unconﬁrmed diagnoses, it is
conceivable that some may have been wrongly classiﬁed.
Despite this, reanalysis of the dataset with inclusion of these
patients does not alter the principal ﬁndings (data not
shown). Second, our material included patients with Lo¨f-
gren’s syndrome who at presentation have a high pretest
probability of sarcoidosis and thus may have had a sub-
stantial impact on the coefﬁcients in the models. However,
the ﬁndings are not essentially altered on reanalysis of the
dataset with the exclusion of these patients [AUC (95 % CI)
for the ﬁnal and basic models were 0.926 (0.885–0.967) and
0.881 (0.827–0.934), respectively, p = 0.02]. Third, a high
number of variables per case may increase the risk of
overﬁtting the regression model. This is especially so if the
goal is to gain insight into the relationship between the
predictors and the outcome in an explanatory model.
Because the main goal of the present study was to identify
potential predictors of a diagnosis, the model structure and
number of variables are less critical [16, 28]. Finally, and not
least, our study is retrospective and the models lack external
validation. The median area under the curves of repeated
random subsampling gives a more realistic estimate of the
diagnostic accuracy than merely ROC curve analysis of the
same dataset used for model estimation. However, in a dif-
ferent clinical population with a different spectrum of dis-
ease and where the laboratory analyses are done differently,
the diagnostic accuracy may be different. Thus, a prospec-
tive study that addresses the utility of our model as a diag-
nostic tool in sarcoidosis would further strengthen the
validity of our results.
The role of NKT cells and activated CD8? T cells in
sarcoidosis pathophysiology is not yet clear. A deﬁciency
of a NKT cell subset in sarcoidosis has been reported [29].
Conversely, the high fractions of NKT cells in some
patients in the nonsarcoidosis group (Fig. 3) may reﬂect
involvement of NKT cells in the immunopathology of
speciﬁc DPLDs, such as HP [10], as NKT cells contain
subsets with both regulatory and cytotoxic functions, as
well as antitumor activity [30]. HLA-DR expression on T
cells may play a role in regulating or limiting a speciﬁc
T-cell response to an antigen [31]. The fraction of HLA-
DR? CD8? lymphocytes increases in some autoimmune
diseases, possibly as a part of normal immunoregulation
[32], although its exact role is unclear.
In conclusion, the diagnostic accuracy of BALF cell
proﬁles in sarcoidosis is good and can be increased by
adding the NKT cell fraction and HLA-DR expression on
CD8? lymphocytes, thus leading to a better discrimination
between sarcoidosis and nonsarcoidosis. These ﬁndings
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should be validated in other centers, preferably in a pro-
spective setting.
Acknowledgments Assistance provided by Gine Eggen and col-
leagues in the Unit for cytometry, Department of Immunology and
Transfusion Medicine, St. Olavs University Hospital was greatly
appreciated, and the unit’s expertise in ﬂow cytometry has been
invaluable to this study.
Conﬂict of interest None.
References
1. Wells AU, Hirani N (2008) Interstitial lung disease guideline.
Thorax 63(Suppl 5):v1–v58. doi:10.1136/thx.2008.101691
2. Drent M, Mansour K, Linssen C (2007) Bronchoalveolar lavage
in sarcoidosis. Semin Respir Crit Care Med 28(5):486–495
3. Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell
F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M,
Cormier Y (2003) Clinical diagnosis of hypersensitivity pneu-
monitis. Am J Respir Crit Care Med 168(8):952–958
4. Cordeiro CR, Jones JC, Alfaro T, Ferreira AJ (2007) Broncho-
alveolar lavage in occupational lung diseases. Semin Respir Crit
Care Med 28(5):504–513
5. Meyer KC (2007) Bronchoalveolar lavage as a diagnostic tool.
Semin Respir Crit Care Med 28(5):546–560. doi:10.1055/s-2007-
991527
6. (1999) Statement on sarcoidosis. Am J Respir Crit Care Med
160(2):736–755
7. Kantrow SP, Meyer KC, Kidd P, Raghu G (1997) The CD4/CD8
ratio in BAL ﬂuid is highly variable in sarcoidosis. Eur Respir J
10(12):2716–2721
8. Meyer KC, Soergel P (1999) Variation of bronchoalveolar lym-
phocyte phenotypes with age in the physiologically normal
human lung. Thorax 54(8):697–700
9. Heron M, Claessen AME, Grutters JC, Van Den Bosch JMM
(2010) T-cell activation proﬁles in different granulomatous inter-
stitial lung diseases—a role for CD8?CD28null cells? Clin Exp
Immunol 160(2):256–265. doi:10.1111/j.1365-2249.2009.04076.x
10. Korosec P, Osolnik K, Kern I, Silar M, Mohorcic K, Kosnik M
(2007) Expansion of pulmonary CD8?CD56?natural killer T
cells in hypersensitivity pneumonitis*. Chest 132(4):1291–1297.
doi:10.1378/chest.07-0128
11. Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in
England. A review of 136 cases after ﬁve years’ observation. Br
Med J 2(5261):1165–1172
12. Baughman RP (2007) Technical aspects of bronchoalveolar
lavage: recommendations for a standard procedure. Semin Respir
Crit Care Med 28(05):475–485. doi:10.1055/s-2007-991520
13. Albert A (1982) On the use and computation of likelihood ratios
in clinical chemistry. Clin Chem 28(5):1113–1119
14. Barry SM, Condez A, Johnson MA, Janossy G (2002) Determi-
nation of bronchoalveolar lavage leukocyte populations by ﬂow
cytometry in patients investigated for respiratory disease.
Cytometry 50(6):291–297
15. Domagała-Kulawik J, Skirecki T, Maskey-Warzechowska M,
Grubek-Jaworska H, Chazan R (2012) Bronchoalveolar lavage
total cell count in interstitial lung diseases—does it matter?
Inﬂammation 35(3):803–809. doi:10.1007/s10753-011-9378-5
16. Sauerbrei W, Royston P, Binder H (2007) Selection of important
variables and determination of functional form for continuous
predictors in multivariable model building. Stat Med 26(30):
5512–5528
17. Metz CE (1978) Basic principles of ROC analysis. Semin Nucl
Med 8(4):283–298
18. Moons KG, de Groot JA, Linnet K, Reitsma JB, Bossuyt PM
(2012) Quantifying the added value of a diagnostic test or marker.
Clin Chem 58(10):1408–1417. doi:10.1373/clinchem.2012.
182550
19. Steyerberg EW, Harrell FE Jr, Borsboom GJJM, Eijkemans MJC,
Vergouwe Y, Habbema JDF (2001) Internal validation of pre-
dictive models: efﬁciency of some procedures for logistic
regression analysis. J Clin Epidemiol 54(8):774–781. doi:10.
1016/S0895-4356(01)00341-9
20. Hallan S, Asberg A, Edna TH (1997) Estimating the probability
of acute appendicitis using clinical criteria of a structured record
sheet: the physician against the computer. Eur J Surg
163(6):427–432
21. Efron B (1982) 9. Random subsampling. In: The Jackknife, the
bootstrap and other resampling plans. SIAM, Philadelphia,
p 69–73. doi:10.1137/1.9781611970319.ch9
22. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing
the areas under two or more correlated receiver operating char-
acteristic curves: a nonparametric approach. Biometrics
44(3):837–845
23. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du
Bois RM, DrentM, Haslam PL, KimDS, Nagai S, Rottoli P, Saltini
C, Selman M, Strange C, Wood B (2012) An ofﬁcial American
Thoracic Society clinical practice guideline: the clinical utility of
bronchoalveolar lavage cellular analysis in interstitial lung disease.
Am J Respir Crit Care Med 185(9):1004–1014
24. Drent M, van Nierop MA, Gerritsen FA, Wouters EF, Mulder PG
(1996) A computer program using BALF-analysis results as a
diagnostic tool in interstitial lung diseases. Am J Respir Crit Care
Med 153(2):736–741
25. De Smet D, Martens GA, Berghe BV, Meysman M, Heylen O,
Gorus FK, De Waele M (2010) Use of likelihood ratios improves
interpretation of laboratory testing for pulmonary sarcoidosis.
Am J Clin Pathol 134(6):939–947. doi:10.1309/ajcpnc7
sthg0fwmp
26. Drent M, Jacobs JA, Cobben NA, Costabel U, Wouters EF,
Mulder PG (2001) Computer program supporting the diagnostic
accuracy of cellular BALF analysis: a new release. Respir Med
95(10):781–786
27. Li QH, Li HP, Shen YP, Zhao L, Shen L, Zhang Y, Jiang DH,
Baughman RP (2012) A novel multi-parameter scoring system
for distinguishing sarcoidosis from sputum negative tuberculosis.
Sarcoidosis Vasc Diffuse Lung Dis 29(1):11–18
28. Copas JB (1983) Regression, prediction and shrinkage. J R Stat
Soc Ser B 45(3):311–354. doi:10.2307/2345402
29. Ho L-P, Urban BC, Thickett DR, Davies RJO, McMichael AJ
(2005) Deﬁciency of a subset of T cells with immunoregulatory
properties in sarcoidosis. Lancet 365(9464):1062–1072. doi:10.
1016/s0140-6736(05)71143-0
30. Wajchman HJ, Pierce CW, Varma VA, Issa MM, Petros J, Dom-
browski KE (2004) Ex vivo expansion of CD8?CD56? and
CD8?CD56- natural killer T cells speciﬁc for MUC1 mucin.
Cancer Res 64(3):1171–1180. doi:10.1158/0008-5472.can-3254-2
31. Ødum N, Yoshizumi H, Okamoto Y, Kamikawaji N, Kimura A,
Nishimura Y, Sasazuki T (1992) Signal transduction by HLA
class II molecules in human T cells: induction of LFA-1-depen-
dent and independent adhesion. Human Immunol 35(2):71–84.
doi:10.1016/0198-8859(92)90014-e
32. Imamichi H, Lempicki RA, Adelsberger JW, Hasley RB,
Rosenberg A, Roby G, Rehm CA, Nelson A, Krishnan S, Pavlick
M, Woods CJ, Baseler MW, Lane HC (2012) The CD8?HLA-
DR? T cells expanded in HIV-1 infection are qualitatively
identical to those from healthy controls. Eur J Immunol. doi:10.
1002/eji.201142046
Lung
123
Author's personal copy
Research Article
Bronchoalveolar Lavage Fluid IFN-𝛾+ Th17 Cells and Regulatory
T Cells in Pulmonary Sarcoidosis
Anders Tøndell,1,2,3 Torolf Moen,2,4 Magne Børset,2,3 Øyvind Salvesen,3
Anne Dorthea Rø,2,4 and Malcolm Sue-Chu1,5
1 Department of Thoracic Medicine, St. Olavs University Hospital, Postboks 3250 Sluppen, 7006 Trondheim, Norway
2Department of Immunology and Transfusion Medicine, St. Olavs University Hospital, 7006 Trondheim, Norway
3Department of Cancer Research andMolecularMedicine, Norwegian University of Science and Technology, 7489 Trondheim, Norway
4Department of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology,
7489 Trondheim, Norway
5Department of Circulation and Imaging, Norwegian University of Science and Technology, 7489 Trondheim, Norway
Correspondence should be addressed to Anders Tøndell; anders.tondell@gmail.com
Received 26 January 2014; Accepted 9 April 2014; Published 5 May 2014
Academic Editor: Teresa Zelante
Copyright © 2014 Anders Tøndell et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In sarcoidosis, increased Th17 cell fractions have been reported in bronchoalveolar lavage fluid, and elevated numbers of Th17
cells producing IFN-𝛾 have been observed in peripheral blood. The balance between Th1, Th17, and FoxP3+ CD4+ T cell subsets
in sarcoidosis remains unclear. Bronchoalveolar lavage fluid cells, from 30 patients with sarcoidosis, 18 patients with other diffuse
parenchymal lung diseases, and 15 healthy controls, were investigated with flow cytometry for intracellular expression of FoxP3. In a
subset of the patients, expression of the cytokines IL17A and IFN-𝛾was investigated.The fractions of FoxP3+ CD4+ T cells andTh17
cells were both lower in sarcoidosis compared to controls (𝑃 = 0.017 and 𝑃 = 0.011, resp.).The proportion ofTh17 cells positive for
IFN-𝛾was greater in sarcoidosis than controls (median 72.4% versus 31%, 𝑃 = 0.0005) and increased with radiologic stage (𝑁 = 23,
rho = 0.45, and 𝑃 = 0.03). IFN-𝛾+Th17 cells were highly correlated with Th1 cells (𝑁 = 23, rho = 0.64, and 𝑃 = 0.001), and the
ratio of IFN-𝛾+Th17/FoxP3+ CD4+ T cells was prominently increased in sarcoidosis. IFN-𝛾+Th17 cells may represent a pathogenic
subset of Th17 cells, yet their expression of IFN-𝛾 could be a consequence of a Th1-polarized cytokine milieu. Our results indicate
a possible immune cell imbalance in sarcoidosis.
1. Introduction
Sarcoidosis is a granulomatous disease with a predilection
for the lungs and lymphatic tissue and is characterized by
increased fractions and number of IFN-𝛾-producing T helper
cells (Th1 cells) in inflamed tissue [1, 2]. A current hypothesis
about the etiology is that an inhaled antigen, which may
be persistent and poorly degradable, provokes a Th1 type
immune reaction. Both mycobacterial proteins and DNA
fromPropionibacteriumacneshave been identified as possible
candidate antigens [3].
The discovery of the CD4+ T cell subsets regulatory T
cells and laterTh17 cells has modified the traditional concept
of Th1- or Th2-polarized adaptive immune responses [4–
7]. Whereas regulatory T cells, which are characterized by
expression of the transcription factor FoxP3, have a pivotal
role in maintaining immune homeostasis and preventing
autoimmunity [8, 9];Th17 cells produce the potent proinflam-
matory cytokine IL-17 and have a crucial role in host immu-
nity towards extracellular bacterial and fungal pathogens [10].
Both Th17 cells and FoxP3+ CD4+ T cells have been impli-
cated in various human diseases with suspected autoimmune
etiology, such as rheumatoid arthritis, inflammatory bowel
disease, multiple sclerosis, and psoriasis [10–12]. Intriguingly,
the putative sarcoidosis antigensMycobacterium tuberculosis
and Propionibacterium acnes have both been reported to
trigger strong Th17 responses [10]. Furthermore, Th17 cells
recruit Th1 cells to the lungs during a mycobacterial infec-
tion and are required for proper formation of granulomas
[13].
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Increased Th17 cell fractions in peripheral blood and
bronchoalveolar lavage fluid (BALF), and surrounding the
central core of the granuloma on tissue specimens have been
reported in sarcoidosis [14]. Within theTh17 cell population,
there are subsets secreting different cytokines, including
TNF-𝛼 and IFN-𝛾, with distinct effector functions [15]. IFN-
𝛾+ Th17 cells have been observed in elevated numbers in
inflamed tissue in various conditions in man and mice [16–
18]. In sarcoidosis, peripheral bloodTh17 cells were reported
to contain an increased fraction of IFN-𝛾+ cells compared to
controls, although the IFN-𝛾median fluorescent intensity of
these cells was decreased [19].
Reports on regulatory T cells in sarcoidosis are conflict-
ing. FoxP3+ CD4+ T cells are present in increased numbers
in and around granulomas [20]. However, in BALF both
increased [21] and decreased frequencies [22] have been
reported. Interestingly, an imbalance of the regulatory T
cells and the proinflammatory Th17 cells may contribute to
the pathophysiology of autoimmune diseases [23–26]. These
two CD4+ T cell subsets share common promoting factors
and chemokine receptors that constitute developmental and
functional links [27, 28].
In this study, we investigated the proportion of CD4+ T
cell subsets expressing FoxP3 and, upon stimulation, IL17 or
IFN-𝛾 in patients with sarcoidosis, other DPLDs, and healthy
control subjects. The aim of the study was to investigate the
fractions of FoxP3+ CD4+ T cells,Th1,Th17, and IFN-𝛾+Th17
cells in BALF and to assess the hypothesis about an imbalance
between these subsets in sarcoidosis. We also investigated if
these phenotypes correlated with the radiological staging of
the sarcoidosis.
2. Materials and Methods
2.1. Study Population. Patients who underwent diagnostic
workup with bronchoscopy and bronchoalveolar lavage in
our clinic between November 2010 and September 2012
for possible diffuse parenchymal lung disease (DPLD) were
eligible for inclusion in the study if they had a BALF
lymphocyte fraction greater than 5% of the leucocytes and
were not receiving systemic therapy with corticosteroid or
methotrexate. We included 30 patients with sarcoidosis and
18 patients with other DPLDs (hypersensitivity pneumonitis:
𝑁 = 5; idiopathic pulmonary fibrosis: 𝑁 = 2; non-
specific interstitial pneumonia: 𝑁 = 1; connective tissue
disease or medication-associated lung disease: 𝑁 = 2;
pneumoconiosis: 𝑁 = 1; unspecified DPLD: 𝑁 = 7).
Patients with a concluding non-DPLD clinical diagnosis were
not included. For this study, the diagnosis of sarcoidosis
was considered certain if clinical presentation and thoracic
imaging were consistent with pulmonary sarcoidosis and
there were noncaseating granulomas in endobronchial or
transbronchial biopsy specimens or from endobronchial
ultrasound transbronchial aspirations of enlarged hilar or
mediastinal lymph nodes [29]. Histological demonstration
of granuloma was not required for patients with classic
features of Lo¨fgren’s syndrome, defined as bilateral hilar lym-
phadenopathy with fever, erythema nodosum, and/or ankle
arthritis.There were 3, 14, 9, 2, and 2 sarcoidosis patients with
radiological staging 0, 1, 2, 3, and 4, respectively, according
to Scadding [30], and 5 patients presented with Lo¨fgren’s
syndrome.
Investigation of intracellular expression of IL-17A and
IFN-𝛾 after mitogen stimulation was performed in a sub-
group of the patients: sarcoidosis: 𝑁 = 23 (3 patients with
Lo¨fgren’s syndrome); other DPLDs:𝑁 = 11 (hypersensitivity
pneumonitis: 𝑁 = 3; idiopathic pulmonary fibrosis: 𝑁 =
1; connective tissue disease or medication associated lung
disease:𝑁 = 2; unspecified DPLD:𝑁 = 5).
Eight male and 7 female healthy control subjects were
recruited by advertising on the hospital website. All were
nonsmokers with no history of allergy, asthma, or other lung
diseases, and had normal chest radiography. All healthy con-
trol subjects and all patients except two were Caucasians of
Scandinavian descent. Characteristics of the study population
are displayed in Table 1.
Written informed consent was obtained from all subjects,
and the study was approved by the Regional Ethics Commit-
tee (Ref.nr.: 2010/1939-4).
2.2. BAL Procedure. BAL was performed as previously
described [31]. The choice of the lavage site was guided by
the location of parenchymal pathology on high resolution
computed tomography (HRCT), or if indifferent, the right
middle lobe was chosen. With the bronchoscope in a wedged
position in a segmental bronchus, 2-3 aliquots of 60mL
phosphate-buffered saline (hospital pharmacy at Haukeland
University Hospital, Bergen, Norway) were instilled and
retrieved by applying gentle suction. The second and third
fractions of BALF were pooled and filtered through a Falcon
Cell strainerwith 100𝜇mnylonmesh (Becton,Dickinson and
Company (BD) Biosciences, Mountain view, CA) and stored
at 4∘C until processing within 4 hours of collection.
2.3. Total and Differential Cell Counts. ADVIA 120 Hema-
tology System (Siemens AG, Erlangen, Germany) was used
for determination of total cell count. Smears were prepared
by cytocentrifugation (Hettich Universal 320, DJB Labcare
Ltd., Buckinghamshire, England) and stained with May
Gru¨nwald/Giemsa. Differential cell counts were done on a
minimum of 300 cells.
2.4. Mitogen Stimulation. The cells were processed accord-
ing to the recommendations in the human Th17/Treg
phenotyping kit (BD Biosciences) (see supplementary
Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2014/438070; tube 4). Briefly, 1-2
×106 cells were incubated at 37∘C and 5% CO
2
for 5 hours
in Roswell Park Memorial Institute medium (RPMI) with
10% fetal calf serum (FCS) with and without phorbol-12-
myristate-13-acetate (PMA) at 50 ng/mL and ionomycin
1 𝜇g/mL, in the presence of GolgiStop, a protein transport
inhibitor (BD Biosciences). The cells were fixed by BD FoxP3
buffer set, buffer A (BD Biosciences), and stored for <6
months in a medium of 90% FCS and 10% dimethyl sulfoxide
(DMSO) at −80∘C until batch processing.
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Table 1: Basic characteristics of the study population.
Characteristic Sarcoidosis(𝑁 = 30)
Other DPLDs
(𝑁 = 18)
Healthy controls
(𝑁 = 15) 𝑃
∗
Age, years (range) 46 (37–56)## 63 (48–72)§§ 35 (30–49) 0.03
Sex (male/female) 23/7 11/7 8/7 0.25
Smokers (current/former/never) 1/9/20 4/7/7 0/3/12 0.03∗∗
FEV1, percentage of predicted 80 (68–90) 75 (63–88)§§ 101 (95–104) <0.001
FEV1/FVC 0.78 (0.73–0.83)# 0.82 (0.78–0.88) 0.85 (0.81–0.86) 0.03
TLCO, percentage of predicted 92 (77–102)## 57 (53–69)§§ 103 (98–109) 0.01
Data are shown as median (IQR) unless otherwise stated. ∗𝑃 values represent pairwise comparison between Sarcoidosis and healthy controls with Mann-
Whitney 𝑈 test conducted if significant differences were found with Kruskal-Wallis test. §§𝑃 < 0.01 compared to healthy controls. #𝑃 < 0.05 and ##𝑃 < 0.01
compared to other DPLD. ∗∗𝑃 value from chi-squared test. DPLD: diffuse parenchymal lung disease; FEV1: forced expiratory volume in 1 second; FVC: forced
vital capacity; TLCO: transfer factor of the lung for carbon monoxide.
2.5. Antibody Staining and Flow Cytometry. For surface
antigen staining, BALF was centrifuged for 5min at 500×g,
and the cell pellet incubated for 15min with the antibodies
as listed (supplementary Table 1, tubes 1-2). For detection of
FoxP3+ CD4+ T cells, the unstimulated cells were incubated
with permeabilization buffer (BD Biosciences) and then
stained with antibodies to surface and intracellular antigens
(supplementary Table 1, tube 3). In the mitogen-stimulated
samples, the thawed cells were incubated with permeabiliza-
tion buffer (BDBiosciences) and then stainedwith antibodies
to surface and intracellular antigens (supplementary Table 1,
tube 4). Unstimulated cells were used as negative controls for
gating.
A minimum of 10 000 and 50 000 cells were analysed for
surface and intracellular antigens, respectively, using a FACS
Canto I flow cytometer (BD Biosciences), with FACS DIVA
software (BD Biosciences). Lymphocytes were identified by
their low side scatter (SSc) and forward scatter (FSc), and
T cells were identified as CD3+ lymphocytes. T cells were
further gated by expression of CD4 and CD8 into the two
main subsets, CD4+ and CD8+ (cytotoxic) T cells. Gating of
CD4+ T cell subsets is displayed in Figure 1.
2.6. Statistical Methods. Group comparison for continuous
and categorical data was done by Kruskal-Wallis test and
Pearson chi-squared test, respectively. Pairwise comparison
was donewithMann-WhitneyU test if a significant difference
was found with Kruskal-Wallis test. Spearman’s rank corre-
lation test was used for investigating correlation. Statistical
analyses were done in R, a language and environment
for statistical computing (R Core Team, R Foundation for
Statistical Computing, Vienna, Austria). A 𝑃 value of < 0.05
was considered to be statistically significant.
3. Results
3.1. FoxP3+ CD4+ T Cells. The fraction of FoxP3+ CD4+
T cells in BALF was significantly lower in patients with
sarcoidosis compared to other DPLDs and HCs (median
(IQR): 3.4% (2.1–4.8) versus 7.1% (4.4–12.6), 𝑃 = 0.001 and
versus 5.3% (4.4–7.0), 𝑃 = 0.017) (Figure 2(a)).
Themajority of FoxP3+ CD4+ T cells expressedCD27 and
CD39 in all groups, with no significant differences between
sarcoidosis and healthy controls (𝑃 = 0.063 and 𝑃 = 0.51,
resp.) (Table 2). Expression of CD27 and CD39 on FoxP3+
CD4+ T cells was higher in other DPLDs compared to
sarcoidosis (𝑃 = 0.01 and 𝑃 = 0.03, resp.), and in other
DPLDs compared to healthy controls (𝑃 = 0.001 and 𝑃 =
0.02, resp.).
3.2. Th17, IFN-𝛾+ Th17, and Th1 Cells. Compared to healthy
control subjects, the Th17 cell fraction of CD4+ T cells was
45% lower (𝑃 = 0.011) and the proportion of Th17 cells
positive for IFN-𝛾 was over twofold greater (𝑃 = 0.0005) in
sarcoidosis (Figure 2 and Table 3). These fractions were not
significantly different between patients with sarcoidosis and
other DPLDs. Fractions ofTh1 (IFN-𝛾+ CD4+) cells were not
significantly different between any of the groups.
Flow cytometry dot plots with a display of FoxP3+ CD4+
T cells,Th1,Th17, and IFN-𝛾+Th17 cells from a representative
sarcoidosis and control subject are shown in Figure 1.
The fraction of IFN-𝛾+ Th17 cells increased with radio-
logic stage of sarcoidosis (𝑛 = 23, rho = 0.45, and 𝑃 = 0.03)
(Figure 3).
3.3. The Relationship between Th1, Th17, IFN-𝛾+ Th17, and
FoxP3+ CD4+ T Cell Subsets in Sarcoidosis. In patients with
sarcoidosis, fractions ofTh17 cells weremoderately correlated
to fractions of Th1 cells (𝑁 = 23, rho = 0.53, and 𝑃 = 0.009),
while we found no significant correlation between Th17 cells
and FoxP3+ T helper cells (𝑁 = 23, rho = 0.25, and 𝑃 = 0.26)
or between Th1 cells and FoxP3+ T helper cells (𝑁 = 23,
rho = −0.25, and 𝑃 = 0.26).
IFN-𝛾+ fractions ofTh17 cells were highly correlated with
Th1 cells in patients with sarcoidosis (𝑁 = 23, rho = 0.64, and
𝑃 = 0.001). This correlation was also found in an analysis of
all patients and healthy controls combined (𝑁 = 48, rho =
0.75, 𝑃 < 0.0001) (Figure 4(a)), and in the other individual
groups (healthy controls:𝑁 = 15, rho = 0.91, and𝑃 < 0.00001
and other DPLDs: 𝑁 = 11, rho = 0.7, and 𝑃 = 0.02).
The ratio of Th17/FoxP3+ CD4+ T cells was not significantly
different between the groups (𝑃 = 0.09, Kruskal-Wallis test),
while the ratio of Th1/FoxP3+ CD4+ T cells was higher in
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Figure 1: T helper cells in bronchoalveolar lavage fluid: regulatory T cells, Th1, Th17, and IFN-𝛾+ Th17 cells. Flow cytometry dot plots of
bronchoalveolar lavage fluid CD4+ T cells gated by expression of FoxP3, IL17 (synonymous to IL-17A), and IFN-𝛾 from a healthy control
subject ((a)–(c)) and a patient with sarcoidosis ((d)–(f)). The T cell subsets are defined as follows: Th1 cells: IFN-𝛾+ CD4+; Th17 cells: IL17+
CD4+; regulatory T cells: FoxP3+ CD4+ and IFN-𝛾+; Th17 cells: IFN-𝛾+ IL-17+ CD4+. Thus, the Th17 cells include the cells in both upper
quadrants of plots (c) and (f). The patient and healthy control are representative examples. Gates for IL17 and IFN-𝛾 were set according to
unstimulated CD4+ T cells. Very few cells express intracellular IL-17 or IFN-𝛾 prior to stimulation (median 0.0% in fractions of CD4+ T cells
for both IL-17 and IFN-𝛾).
Table 2: BALF lymphocyte subsets assessed by flow cytometry.
Characteristic Sarcoidosis(𝑁 = 30)
Other DPLDs
(𝑁 = 18)
Healthy controls
(𝑁 = 15) 𝑃
∗
CD3+ T cells (% of lymphocytes) 96.2 (95.3–97.5)## 92.3 (87.0–94.6) 92.9 (89.7–94.6) <0.0001
CD4/CD8 ratio 6.1 (4.1–10.8)## 2.0 (0.5–3.3) 2.6 (2.1–3.4) <0.0001
HLA-DR+ (% of CD4+ T cells) 75.1 (60.9–80.7) 76.1 (70.2–84.4)§§ 44.9 (36.1–56.7) <0.0001
HLA-DR+ (% of CD8+ T cells) 47.3 (42.2–56.3)## 70.0 (58.6–78.1)§§ 30.4 (25.9–33.9) <0.0001
FoxP3+ (% of CD4+ T cells) 3.4 (2.1–4.8)## 7.1 (4.4–12.6) 5.3 (4.4–7.0) 0.02
CD39+ (% of FoxP3+ CD4+ T cells) 61 (34–78)# 80 (68–84)§ 55 (45–66) 0.51
CD27+ (% of FoxP3+ CD4+ T cells) 86 (80–93)# 95 (87–97)§§ 78 (72–86) 0.06
Data are shown as median (IQR). ∗𝑃 values represent pairwise comparison between sarcoidosis and healthy controls with Mann-Whitney𝑈 test conducted if
significant differences were found with Kruskal-Wallis test. §𝑃 < 0.05 and §§𝑃 < 0.01 compared to healthy controls. #𝑃 < 0.05 and ##𝑃 < 0.01 compared to
other DPLD.
sarcoidosis compared to other DPLDs and compared to HC
(median (IQR): 21.7 (14.4–35.2) versus 6.2 (2.8–13.5), 𝑃 =
0.002, and versus 9.5 (8.9–13-6), 𝑃 = 0.009).The ratio of IFN-
𝛾+Th17/FoxP3+ CD4+ T cells was considerably increased in
sarcoidosis compared to other DPLDs or HC (Figure 4(b)).
The lymphocyte fraction was 2.5-fold greater in patients
with sarcoidosis compared to HC (Table 4). BALF lympho-
cyte subset fractions in the study groups are summarized in
Table 2. The CD4/CD8 ratio, HLA-DR+ CD4+, and HLA-
DR+ CD8+ T cells were significantly higher in patients with
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Figure 2: Bronchoalveolar lavage fluid fractions of FoxP3+ CD4+ T cells, Th17, and IFN-𝛾+Th17 in sarcoidosis, other DPLDs, and healthy
control subjects. (a) Lower fractions of regulatory T cells, defined as FoxP3+ CD4+ T cells, in sarcoidosis compared to other DPLDs and
HC. (b) Lower Th17 cell fractions of CD4+ T cells in sarcoidosis compared to HC (median: 2.5% versus 4.5%, 𝑃 = 0.011). (c) Higher IFN-
𝛾+ fraction of Th17 cells in sarcoidosis compared to HC (median: 72.4% versus 31%, 𝑃 = 0.0005). Pairwise comparisons were done with
Mann-Whitney U test. DPLD: Diffuse parenchymal lung disease; HC: healthy controls.
sarcoidosis compared to HC (𝑃 < 0.0001, 𝑃 < 0.0001, and
𝑃 < 0.0001, resp.). Expression of HLA-DR on CD8+ T cells
was higher in other DPLDs compared to healthy controls and
sarcoidosis (𝑃 = 0.0001 and 𝑃 = 0.0008, resp.) and on CD4+
T cells compared to healthy controls (𝑃 = 0.0002).
4. Discussion
In this study, IFN-𝛾 expression in Th17 cells was over
twofold greater in sarcoidosis than in healthy controls and
increased with the radiologic stage of sarcoidosis. Fractions
of BALF FoxP3+ CD4+ T cells and Th17 cells were lower in
sarcoidosis compared to healthy controls. Furthermore, we
found a high degree of correlation between fractions of IFN-
𝛾+ Th17 and Th1 cells, and the ratio of IFN-𝛾+ Th17/FoxP3+
CD4+ T cells was prominently increased in sarcoidosis
compared to other DPLDs or HCs. This may indicate a
strongTh1 immune response in sarcoidosis patients resulting
in deviation of CD4+ T cell differentiation from FoxP3+
CD4+ T cells and plain Th17 cells into IFN-𝛾+Th17 and Th1
cells.
To our knowledge, investigation of BALF IFN-𝛾+ Th17
cells in sarcoidosis is limited to one study by ten Berge et al.
[32]. In that study expression of IFN-𝛾was reported in a large
fraction of BALFTh17 cells in 5 patients. Our finding, stating
that themajority of BALFTh17 cells in sarcoidosis are IFN-𝛾+,
is in line with reports on Th17 cells in peripheral blood from
patients with sarcoidosis [19, 32]. In the study by Richmond
et al., peripheral blood IFN-𝛾+ Th17 cells of sarcoidosis
patients had significantly lower mean fluorescence intensity
for IFN-𝛾 compared to cells from control subjects, indicating
a reduced capacity in these cells to produce IFN-𝛾 [19]. In
sarcoidosis, T cells exhibit a more differentiated phenotype
in the affected organ [33, 34]. Thus, the immune process in
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Table 3: BALF lymphocyte subsets assessed by flow cytometry of mitogen stimulated cells.
Mitogen stimulated cells Sarcoidosis(𝑁 = 23)
Other DPLDs
(𝑁 = 11)
Healthy controls
(𝑁 = 15) 𝑃
∗
Th1 (IFN-𝛾+, % of CD4+ T cells) 75.5 (62.6–79.4) 62.1 (46.7–75.0) 65.7 (41.5–69.6) n.s
Th17 cells (% of CD4+ T cells) 2.5 (1.4–4.5) 3.0 (1.8–6.6) 4.5 (3.2–8.5) 0.01
IFN-𝛾+Th17 (% of Th17) 72.4 (57.1–83.8) 65.5 (39.9–85.9) 31.0 (22.3–49.6) 0.0005
IFN-𝛾+ CD8+ T cells (% of CD8+) 83.4 (69.3–87.9) 83.1 (76.4–94.3) 85.5 (77.5–89.9) n.s
IL17+ CD8+ T cells (% of CD8+) 0.8 (0.5–2.4) 0.5 (0.3–1.4) 1.1 (0.9–1.6) n.s
Data are shown as median (IQR). ∗𝑃 values represent pairwise comparison between sarcoidosis and healthy controls with Mann-Whitney𝑈 test conducted if
significant differences were found with Kruskal-Wallis test. Pairwise comparisons between sarcoidosis and other DPLD or other DPLD and healthy controls
showed no significant difference. n.s: nonsignificant (Kruskal-Wallis test).
Table 4: BALF cellular differential counts assessed by microscopy.
Sarcoidosis
(𝑁 = 30)
Other DPLDs
(𝑁 = 17)
Healthy controls
(𝑁 = 14) 𝑃
∗
Total cell concentration (106/mL) 19 (15–28) 26 (11–29) 14 (12–17) 0.01
Lymphocytes (%) 35 (24–53) 34 (14–48)§ 14 (10–25) 0.001
Neutrophils (%) 2 (1–4)## 6 (2–9) 3 (2–5) 0.15
Mast cells (per 10 squares) 4 (2–9)## 21 (8–63)§§ 2 (0–5) 0.04
Eosinophils (%) 0 (0-1)## 3 (1–9)§§ 0 (0-0) 0.14
Alveolar macrophages (%) 60 (45–73) 47 (26–74)§§ 81 (69–85) 0.001
Data are shown as median (IQR). ∗𝑃 values represent pairwise comparison between sarcoidosis and healthy controls with Mann-Whitney𝑈 test conducted if
significant differences were found with Kruskal-Wallis test. §𝑃 < 0.05 and §§𝑃 < 0.01 compared to healthy controls. #𝑃 < 0.05 and ##𝑃 < 0.01 compared to
other DPLD. Differential counts were missing for one patient with other diffuse parenchymal lung disease (DPLD) and one healthy control.
sarcoidosis may be better characterized in studies on BALF
cells.
Fractions of BALF Th17 cells were lower in sarcoidosis
patients compared to controls in the present study. This
is consistent with another study in which IL-17A mRNA
expression in sorted CD4+ T cells was investigated [35],
but at variance with other studies that detected intracellular
expression of IL-17A by flow cytometry [14, 19, 32], several
possible explanations may account for the different results.
The gating of IL17+ from IL17− CD4+ T cells may differ
between the studies. We used unstimulated cells from the
individual patients to set the gates, which we thinkmay be an
appropriate way to delineate the IL17+ from the IL17− popu-
lations. Importantly, differences in genetic background may
influence the sarcoidosis immune process. Our results are
similar to those of the study from Sweden [35], but at variance
with theAmerican study [19], where approximately half of the
patients had Afro-American background, and 14/37 patients
had sarcoidosis of the skin. In contrast, all of our patients
had pulmonary sarcoidosis. In addition, Lo¨fgren’s syndrome
is more frequent in sarcoidosis in Scandinavia.
In the present study, the FoxP3+ fractions of CD4+ T cells
in sarcoidosis were lower than in HC. This is in agreement
with one previous study, which reported decreased frequency
of FoxP3+ CD4+ T cells in BALF in patients compared to
HC [22], with relative fractions resembling our results. In
that study FoxP3 mRNA expression was also investigated
and found to be lower in BALF CD4+ T cells from patients
compared toHC. In another study, regulatory T cells in BALF
and peripheral blood were found to be higher in patients
with sarcoidosis than in control subjects [20]. However, they
defined regulatory T cells as CD25bright CD4+ T cells and
confirmed the expression of FoxP3 by, on average, 86.5% of
these cells by a single cell PCR approach. Later, the same
group reported increased fractions of CD45RA−FoxP3bright
CD4+ T cells in peripheral blood and CD4+ FoxP3+ cells
in lymph nodes and granulomas of patients with active
sarcoidosis [36]. The definition of regulatory T cells as
FoxP3bright CD4+ T cells is also different than in the present
study, where regulatory T cells are defined as FoxP3+ CD4+ T
cells,making direct comparison less relevant. As documented
by Darlington et al., FoxP3+ CD4+ T cells are augmented in
lymph nodes compared to BALF [37], thus our finding of
lower fractions of regulatory T cells in BALF in sarcoidosis
may not be inconsistent with increased fractions in lymph
nodes and granulomas.
IFN-𝛾+ Th17 cells may represent a pathogenic subset of
Th17 cells in some autoimmune diseases [17, 18]. In one
study, human Candida albicans-specific but not Staphylococ-
cus aureus-specific Th17 cells were demonstrated to produce
IFN-𝛾 upon stimulation [15]. During the last few years it
has become increasingly clear that there exists plasticity in
the differentiation of T helper cells [38]. IL-12 and IFN-𝛾
influence Th17 cells to change towards IFN-𝛾+ Th17 cells or
Th1-like cells [16, 39]. In a study on Th17 cells recovered
from diseased gut areas in colitis patients, a median of ∼
40% of the Th17 cells was also IFN-𝛾+ [40]. In sarcoidosis,
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Figure 3: Fractions of IFN-𝛾+Th17 cells increase with radiological
stage in sarcoidosis. The relationship of IFN-𝛾+ Th17 cells and
radiological stage in patients with sarcoidosis (𝑁 = 23) and healthy
control subjects (𝑁 = 15). Fractions of IFN-𝛾+ Th17 cells increase
with advancing stage (𝑁 = 23, Spearman’s rho = 0.454, and 𝑃 =
0.03). Bars represent median. HC: Healthy control subjects.
macrophages andTh1-cells are enriched in the granulomatous
lung tissue, and the dominating cytokines in the feedback
loop between these cells are IL-12 and IFN-𝛾. Accordingly,
the reduced Th17 and increased IFN-𝛾+ Th17 cells that we
detected in BALF from the sarcoidosis patients might be a
result of dominating Th1-driving transcription factors and
cytokines. In Figure 4(a) we show that in BALF from patients
and HC there seems to be a clear-cut and highly significant
linear correlation between Th1 cells as a fraction of CD4+ T
cells and IFN-𝛾+ Th17 cells as a fraction of Th17 cells. This
might favor an idea of a common mechanism in switching
of Th17 towards IFN-𝛾+ Th17 and expansion of Th1 cells.
Conversely, it has recently been demonstrated in experiments
with mice, in whom the Th1-driving transcription factors
had been knocked out in T cells, that such na¨ıve T cells
can still develop into pathogenic IFN-𝛾+ Th17 cells and
that IL-23 is essential for differentiation and expansion of
these cells [18]. It may thus seem to be, at least in mice,
a way of differentiation for IFN-𝛾+ Th17 cells independent
of the IFN-𝛾 driving transcription factors. The observation
that the relative frequency of IFN-𝛾+ Th17 cells is higher in
patients with advanced sarcoidosis stage (Figure 3) might be
an indication that these cells possibly have a deleterious effect
in sarcoidosis or might just be the consequence of a more
dominating and pathogenic Th1 immune reaction.
The ratio between IFN-𝛾+ Th17 cells and FoxP3+ CD4+
T cells is markedly raised in patients with sarcoidosis in our
study. Many studies have shown a reciprocal relationship
between Th17 and regulatory T cells [26], and autoimmune
diseases often result from an imbalance in these CD4+ T cell
subsets [41]. An increased ratio between IFN-𝛾+ Th17 cells
and FoxP3+ CD4+ T cells may represent a corresponding
feature of sarcoidosis. A recent study reported an increased
Th17/regulatory T cell ratio in peripheral blood and BALF
in sarcoidosis compared to healthy controls [42]. This was
not found in our study, and fractions of Th17 cell in BALF
were decreased in our study and increased in their study. Both
genetic background and environmental exposures may differ
between a Scandinavian and aChinese population of patients,
possibly accounting for some of these observed differences.
In the present study, CD4+ T cells fromBALF are studied,
which aremore directly involved in the immunologic process
of sarcoidosis than peripheral blood cells. However, there are
some limitations to the study. In our clinic, the number of
patients with other DPLD diagnoses is small, and patients
consist of many different entities. A comparison with a
sufficient number of patients with other granulomatous lung
diseases would be of interest. Furthermore, the number of
sarcoidosis patients in different radiological stages is small,
limiting the use of our data in investigating differences
between patients in different stages of the disease.
In conclusion, we found that the majority of BALF Th17
cells in sarcoidosis are IFN-𝛾+, and the fraction of IFN-𝛾+
Th17 cells was highly correlated with the fraction ofTh1 cells.
Fractions of both Th17 cells and FoxP3+ CD4+ T cells were
lower in sarcoidosis than in HC, and we found a highly
elevated ratio between IFN-𝛾+ fractions of Th17 cells and
FoxP3+ CD4+ T cells, possibly indicating an immune cell
imbalance. Despite the explanation offered in this paper
that the generation of IFN-𝛾+ Th17 cells may be a direct
consequence of aTh1-polarized cytokinemilieu onTh17 cells,
they may still represent a pathogenic subset of Th17 cells,
and further characterization of these cells may provide a
target for therapy and provide additional clues to the complex
immunopathology of sarcoidosis. Functional studies on these
cells and investigations of these cells in patients with different
disease course are warranted.
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